WO2022028506A1 - Sos1 inhibitor, pharmaceutical composition containing same, and use therefor - Google Patents
Sos1 inhibitor, pharmaceutical composition containing same, and use therefor Download PDFInfo
- Publication number
- WO2022028506A1 WO2022028506A1 PCT/CN2021/110746 CN2021110746W WO2022028506A1 WO 2022028506 A1 WO2022028506 A1 WO 2022028506A1 CN 2021110746 W CN2021110746 W CN 2021110746W WO 2022028506 A1 WO2022028506 A1 WO 2022028506A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- ring
- alkyl
- alkylene
- membered
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 229940126271 SOS1 inhibitor Drugs 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 172
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 44
- -1 -OH Chemical group 0.000 claims description 43
- 150000002148 esters Chemical class 0.000 claims description 38
- 239000002207 metabolite Substances 0.000 claims description 38
- 150000001204 N-oxides Chemical class 0.000 claims description 36
- 239000012453 solvate Substances 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 239000000651 prodrug Substances 0.000 claims description 33
- 229940002612 prodrug Drugs 0.000 claims description 33
- 229920006395 saturated elastomer Polymers 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 29
- 150000002430 hydrocarbons Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims description 7
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims description 6
- 206010029748 Noonan syndrome Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 5
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 206010067380 Costello Syndrome Diseases 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- BVXWHRDWRQPPSI-UHFFFAOYSA-N 3-oxabicyclo[2.1.1]hexane Chemical group C1C2CC1CO2 BVXWHRDWRQPPSI-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006334 Gingival Fibromatosis Diseases 0.000 claims description 2
- 208000030839 Hereditary gingival fibromatosis Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical group C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000000062 kidney sarcoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000014104 capillary malformation-arteriovenous malformation syndrome Diseases 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 108700022176 SOS1 Proteins 0.000 description 36
- 102000057028 SOS1 Human genes 0.000 description 36
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 31
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 31
- 101150100839 Sos1 gene Proteins 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 28
- 102000016914 ras Proteins Human genes 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000012141 concentrate Substances 0.000 description 24
- 235000008504 concentrate Nutrition 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 20
- 108010014186 ras Proteins Proteins 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 238000004262 preparative liquid chromatography Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 101150040459 RAS gene Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000011592 zinc chloride Substances 0.000 description 10
- 235000005074 zinc chloride Nutrition 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102100030708 GTPase KRas Human genes 0.000 description 7
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 5
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102200006538 rs121913530 Human genes 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- NNFOVLFUGLWWCL-UHFFFAOYSA-N 1-acetylpiperidin-4-one Chemical compound CC(=O)N1CCC(=O)CC1 NNFOVLFUGLWWCL-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 102100029974 GTPase HRas Human genes 0.000 description 3
- 102100039788 GTPase NRas Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XZQGCSOFHJDIRU-UHFFFAOYSA-N 2-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine Chemical compound C1NCCC2=NC(C)=NC(N)=C21 XZQGCSOFHJDIRU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 102100030264 Pleckstrin Human genes 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 2
- 102100027551 Ras-specific guanine nucleotide-releasing factor 1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- VUDCTLOJEPCNRS-UHFFFAOYSA-N [2-[(dimethylamino)methyl]phenyl]boronic acid Chemical compound CN(C)CC1=CC=CC=C1B(O)O VUDCTLOJEPCNRS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000005883 dithianyl group Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- NKLKQSVCRVETKC-UHFFFAOYSA-N n,n-dimethyl-4-oxocyclohexane-1-carboxamide Chemical compound CN(C)C(=O)C1CCC(=O)CC1 NKLKQSVCRVETKC-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108010026735 platelet protein P47 Proteins 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- AXVSYXUKBUXMHZ-SCSAIBSYSA-N (1R)-1-(4-bromothiophen-2-yl)ethanamine Chemical class C[C@@H](N)C1=CC(Br)=CS1 AXVSYXUKBUXMHZ-SCSAIBSYSA-N 0.000 description 1
- NYBMETYMNLJOEL-SCSAIBSYSA-N (1r)-1-(5-bromothiophen-2-yl)ethanamine Chemical class C[C@@H](N)C1=CC=C(Br)S1 NYBMETYMNLJOEL-SCSAIBSYSA-N 0.000 description 1
- UVCSWVRXAQZOBU-CQSZACIVSA-N 1-[4-[4-[[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]amino]-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]piperidin-1-yl]ethanone Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(CC2)=C1CN2C(CC1)CCN1C(C)=O UVCSWVRXAQZOBU-CQSZACIVSA-N 0.000 description 1
- QQPJQFVOLYRKDW-HXUWFJFHSA-N 1-[4-[4-[[(1R)-1-[5-[2-[(dimethylamino)methyl]phenyl]thiophen-2-yl]ethyl]amino]-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]piperidin-1-yl]ethanone Chemical compound C[C@H](C1=CC=C(C2=C(CN(C)C)C=CC=C2)S1)NC1=NC(C)=NC(CC2)=C1CN2C(CC1)CCN1C(C)=O QQPJQFVOLYRKDW-HXUWFJFHSA-N 0.000 description 1
- HBWUTYLVFYVXML-UHFFFAOYSA-N 1-o-tert-butyl 3-o-methyl 4-oxopiperidine-1,3-dicarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)CCC1=O HBWUTYLVFYVXML-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YNKVCLQNSSTHTD-UHFFFAOYSA-N 3,9-diazaspiro[5.5]undecane Chemical compound C1CNCCC21CCNCC2 YNKVCLQNSSTHTD-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- AKCLKUJMBVMSSE-FPPRHVDESA-N 4-[4-[[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]amino]-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-N,N-dimethylcyclohexane-1-carboxamide Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(CC2)=C1CN2C(CC1)CCC1C(N(C)C)=O AKCLKUJMBVMSSE-FPPRHVDESA-N 0.000 description 1
- XWQVQSXLXAXOPJ-QNGMFEMESA-N 4-[[[6-[5-chloro-2-[[4-[[(2r)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile Chemical compound C1CC(N[C@H](C)COC)CCC1NC1=CC(C=2N=C(NCC3(CCOCC3)C#N)C=CC=2)=C(Cl)C=N1 XWQVQSXLXAXOPJ-QNGMFEMESA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KDHNNFDQOVNBMO-GOSISDBHSA-N 6-cyclobutyl-N-[(1R)-1-[5-[2-[(dimethylamino)methyl]phenyl]thiophen-2-yl]ethyl]-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC=C(C2=C(CN(C)C)C=CC=C2)S1)NC1=NC(C)=NC(CC2)=C1CN2C1CCC1 KDHNNFDQOVNBMO-GOSISDBHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical class NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXEFPNBAQCYBDW-NUBCRITNSA-N C[C@H](C1=CC(=CC(=C1)[N+](=O)[O-])C(F)(F)F)N.Cl Chemical compound C[C@H](C1=CC(=CC(=C1)[N+](=O)[O-])C(F)(F)F)N.Cl UXEFPNBAQCYBDW-NUBCRITNSA-N 0.000 description 1
- IRYZKBAWJHDXGF-CQSZACIVSA-N C[C@H](c1cc(N)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CN(CC1CCOCC1)CC2 Chemical compound C[C@H](c1cc(N)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CN(CC1CCOCC1)CC2 IRYZKBAWJHDXGF-CQSZACIVSA-N 0.000 description 1
- VMZPPIKEJYFKSI-CQSZACIVSA-N C[C@H](c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CN(CC1CCOCC1)CC2 Chemical compound C[C@H](c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CN(CC1CCOCC1)CC2 VMZPPIKEJYFKSI-CQSZACIVSA-N 0.000 description 1
- JZYDBZLENNANEK-SECBINFHSA-N C[C@H](c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CNCC2 Chemical compound C[C@H](c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)Nc1nc(C)nc2c1CNCC2 JZYDBZLENNANEK-SECBINFHSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 241000713863 Kirsten murine sarcoma virus Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101000900711 Mus musculus GRB2-related adaptor protein 2 Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- NDFTZZCWFRWESS-GFCCVEGCSA-N N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-6-cyclobutyl-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC1=NC(C)=NC(CC2)=C1CN2C1CCC1 NDFTZZCWFRWESS-GFCCVEGCSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 0 O=CC1CC*CC1 Chemical compound O=CC1CC*CC1 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
- 108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WUROGHYZXFEDEM-LJQANCHMSA-N [4-[[(1R)-1-[5-[2-[(dimethylamino)methyl]phenyl]thiophen-2-yl]ethyl]amino]-2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-(oxan-4-yl)methanone Chemical compound C[C@H](C1=CC=C(C2=C(CN(C)C)C=CC=C2)S1)NC1=NC(C)=NC(CC2)=C1CN2C(C1CCOCC1)=O WUROGHYZXFEDEM-LJQANCHMSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 150000004844 dioxiranes Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011078 in-house production Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical class O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- AVPKHOTUOHDTLW-UHFFFAOYSA-N oxane-4-carboxylic acid Chemical compound OC(=O)C1CCOCC1 AVPKHOTUOHDTLW-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000005558 triazinylene group Chemical group 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
Definitions
- the present invention relates to SOS1 inhibitors, pharmaceutical compositions containing them, and their use for preventing or treating diseases.
- RAS family proteins are small GTPases encoded by the RAS gene, including KRAS (Kirsten murine sarcoma virus oncogene homolog), HRAS (Harvey murine sarcoma virus oncogene) and NRAS (neuroblastoma RAS virus oncogene homolog) ) and any mutants thereof.
- KRAS Kerrsten murine sarcoma virus oncogene homolog
- HRAS Hardvey murine sarcoma virus oncogene
- NRAS nerveroblastoma RAS virus oncogene homolog
- GTPase activating protein GTPase activating protein
- GAP GTPase activating protein
- GAP GTPase activating protein
- GEF Guanine nucleotide exchange factor
- SOS1 protein Son of Sevenless 1
- Activated RAS protein can activate multiple signal transductions such as RAF/MEK/ERK (MAPK) pathway and PI3K/AKT/mTOR pathway by activating a series of downstream effector proteins (including RAF and phosphatidylinositol kinase PI3K, etc.) pathways, thereby regulating a variety of cellular processes such as cell proliferation, survival, metabolism, motility, angiogenesis, immunity, and growth.
- Mutation of RAS family proteins can inhibit their intrinsic GTPase activity and GAP-induced GTPase activity, resulting in persistent activation of RAS proteins, which in turn leads to persistent activation of downstream effector pathways of RAS proteins.
- RAS is the most frequently mutated oncogene in human cancers.
- KRAS mutations are widely present in a variety of human cancers, including lung, colorectal, and pancreatic cancer. HRAS mutations and NRAS mutations also occur. in different human cancer types. Mutation, overexpression and gene amplification of RAS protein are potential mechanisms of resistance to various anticancer drugs (eg, EGFR antibodies cetuximab and panitumumab, EGFR tyrosine kinase inhibitor osimertinib).
- anticancer drugs eg, EGFR antibodies cetuximab and panitumumab, EGFR tyrosine kinase inhibitor osimertinib.
- SOS1 is the human homolog of the Drosophila SOS protein.
- SOS1 protein is a multi-domain protein composed of 1333 amino acids, consisting of N-terminal domain, Dbl homology domain (Dbl homology, DH), Pleckstrin substrate protein homology domain (Pleckstrin homology, PH), RAS exchange Motif (Ras exchanger motif, REM), CDC25 homology domain and C-terminal domain, among which REM and CDC25 homology domain together form a catalytic domain, which is the catalytic function of SOS1 protein to play a guanine nucleotide exchange factor the required part.
- SOS1 has a critical role in the activation and signaling of mutant RAS proteins in RAS-mutant cancers, and SOS1 knockout inhibits the survival and proliferation of KRAS-mutant tumor cells, and is re-expressed in SOS1-knockout KRAS-mutant tumor cells Catalytic site mutant SOS1, tumor cells could not restore survival and proliferation, demonstrating that the guanine nucleotide exchange catalytic activity of SOS1 is critical for the survival and proliferation of KRAS mutant tumor cells.
- SOS1 can also participate in the signal activation and transduction process of tumor cells through other mechanisms.
- SOS1 can bind to growth factor receptor-binding protein Grb2 to form a SOS1-Grb2 complex, which in turn binds to activated receptor tyrosine kinases (such as EGFR, ErbB2/3/4, VEGFR1/2/3, PDGFR-A/B, FGFR1 /2/3, IGF1R, ALK, ROS1, TRK-A/B/C, RET, c-MET, AXL, etc.), or recruited by other cell surface membrane receptors (such as TCR, BCR, CSF1R).
- SOS1 acts as a guanine nucleotide exchange factor to activate the GTPase RAC1, which is associated with a variety of human cancers and other diseases.
- SOS1 mutations are present in embryonal rhabdomyosarcoma, Sertolioma, cutaneous granulosa cell tumor, and lung adenocarcinoma, and overexpression of the SOS1 protein has also been found in bladder and prostate cancers.
- SOS2 is a homologue of SOS1 in mammalian cells and also functions as a guanine nucleotide exchange factor.
- Mouse knockout model studies have shown that germline knockout of SOS1 can lead to the death of mouse embryos in the second trimester, while adult mice continue to survive after knockout of SOS1. None of the mice exhibited any apparent phenotypic changes, while adult mice with SOS1/2 double knockout died rapidly, suggesting that selective targeting of SOS1 may achieve a high therapeutic index for SOS1-regulated RAS-mutant tumors.
- Inhibiting the binding of SOS1 catalytic site to RAS protein can block SOS1-mediated RAS protein activation, thereby inhibiting RAS protein downstream signaling (such as ERK phosphorylation activation, etc.).
- SOS1 inhibitors with such a mechanism of action can inhibit mutant RAS.
- Protein-dependent tumor cells such as KRAS mutant tumor cell lines have inhibitory effects (eg, inhibition of proliferation, survival, metastasis, etc.).
- the present invention provides compounds useful as SOS1 inhibitors, which have excellent inhibitory activity against SOS1.
- the SOS1 inhibitor of the present invention can inhibit the interaction and activation of SOS1 and RAS protein, especially has a significant inhibitory effect on the interaction between SOS1 and KRAS mutant protein, and can be used for carrying RAS and upstream and downstream proteins (including KRAS, NRAS, HRAS, Receptor tyrosine kinases (eg EGFR, ErbB2/3/4, PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA/B/C, RET, c-MET, VEGFR1/ 2/3, AXL), GAP (eg, NF1) and SOS1) mutated cancer patients provide pharmacological benefit.
- RAS upstream and downstream proteins
- Receptor tyrosine kinases eg EGFR, ErbB2/3/4, PDGFR-A/B, FGFR1/2/3,
- SOS1 inhibitors in RAC1-dependent cancers and other diseases associated with dysregulation of RAS signaling pathway such as neurofibromas, Noonan syndrome (NS), cardio-facial-cutaneous syndrome (CFC) and hereditary gingival fibrosis type 1 Pharmacological benefits will also be provided in tumors.
- the compounds of the invention also have better physicochemical properties (eg solubility, physical and/or chemical stability), improved pharmacokinetic properties (eg improved bioavailability, suitable half-life and duration of action), improved safety (lower toxicity and/or fewer side effects, wider therapeutic window) and other more excellent properties.
- physicochemical properties eg solubility, physical and/or chemical stability
- improved pharmacokinetic properties eg improved bioavailability, suitable half-life and duration of action
- improved safety lower toxicity and/or fewer side effects, wider therapeutic window
- One aspect of the present invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the Said compound has the structure of formula (I):
- R 5 and R 6 at each occurrence are each independently selected from H, C 1-6 alkyl, C 3-10 cyclohydrocarbyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered Heteroaryl and C 6-12 aralkyl; and
- n is an integer selected from 0, 1, 2, 3 and 4.
- compositions comprising a prophylactically or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N- Oxides, isotopically-labeled compounds, metabolites or prodrugs and one or more pharmaceutically acceptable carriers, the pharmaceutical composition is preferably a solid preparation, semi-solid preparation, liquid preparation or gaseous preparation.
- Another aspect of the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro- Use of the medicament or the pharmaceutical composition of the present invention in the preparation of a medicament for use as an SOS1 inhibitor.
- Another aspect of the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro- A drug or a pharmaceutical composition of the present invention for use as an SOS1 inhibitor.
- Another aspect of the present invention provides a method of preventing or treating SOS1-related diseases, the method comprising administering to an individual in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, Polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs or pharmaceutical compositions of the invention.
- alkylene refers to a saturated divalent hydrocarbon radical, preferably a saturated divalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
- alkyl is defined as a linear or branched saturated aliphatic hydrocarbon.
- the alkyl group has 1 to 12, eg, 1 to 6, carbon atoms.
- C 1-6 alkyl refers to a linear or branched group of 1 to 6 carbon atoms (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl) , isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl) optionally substituted by 1 or more (such as 1 to 3) suitable substituents
- halogen substituted where the group is referred to as "haloalkyl”
- haloalkyl eg CH2F , CHF2 , CF3 , CCl3 , C2F5 , C2
- C 1-4 alkyl refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
- alkenyl means a linear or branched monovalent hydrocarbon group containing one double bond and having 2-6 carbon atoms (“C 2-6 alkenyl”).
- the alkenyl groups are, for example, vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2- - Hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl.
- the compound of the present invention contains an alkenylene group, the compound may exist in pure E (ent ought) form, pure Z (zusammen) form, or any mixture thereof.
- alkynyl refers to a monovalent hydrocarbon group containing one or more triple bonds, preferably having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.
- cycloalkyl refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (eg, monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) , cyclooctyl, cyclononyl, or bicyclic, including spiro, fused, or bridged systems (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.)), which are optionally substituted with 1 or more (such as 1 to 3) suitable substituents.
- monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl
- cyclooctyl cyclonony
- the cycloalkyl group has 3 to 15 carbon atoms.
- C 3-6 cycloalkyl refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (eg, cyclopropyl, cyclobutyl, cyclopentyl or cyclo) of 3 to 6 ring carbon atoms hexyl), which is optionally substituted with 1 or more (such as 1 to 3) suitable substituents, eg methyl substituted cyclopropyl.
- cyclohydrocarbylene refers to rings having, for example, 3-10 (suitably 3-8, more suitably 3-6) ring carbons Atoms saturated (ie, “cycloalkylene” and “cycloalkyl") or unsaturated (ie having one or more double and/or triple bonds in the ring) monocyclic or polycyclic (including spirocycles) , fused or bridged systems) hydrocarbon rings including, but not limited to ()cyclopropylidene (ring), ()cyclobutylidene (ring), ()cyclopentylene (ring), ()cyclopentylene Hexyl (ring), ()cycloheptylidene (ring), ()cyclooctyl (ring), ()cyclononyl (ring), ()cyclohexenyl (ring) and the like.
- heterocyclyl As used herein, the terms “heterocyclyl”, “heterocyclylene” and “heterocycle” mean having, for example, 3-10 (suitably 3-8, more suitably 3-6) Ring atoms in which at least one ring atom is a heteroatom selected from N, O, and S and the remaining ring atoms are saturated (ie, heterocycloalkyl) or partially unsaturated (ie, have one or more within the ring double and/or triple bonds) cyclic groups.
- a "3-10 membered (sub)heterocycle (radical)" is one having 2-9 (eg, 2, 3, 4, 5, 6, 7, 8, or 9) ring carbon atoms and is independently selected from N A saturated or partially unsaturated (sub)heterocycle (radical) of one or more (eg 1, 2, 3 or 4) heteroatoms of , O and S.
- heterocyclylenes and heterocycle(radicals) include, but are not limited to: ()oxiranyl, ()aziridinyl, (azetidinyl), ()oxygenide Heterocyclobutyl (oxetanyl), ()tetrahydrofuranyl, ()dioxolinyl (dioxolinyl), ()pyrrolidine, ()pyrrolidone, ()imidazolidinylene, () ) Pyrazolidine, () Pyrrolidene, () Tetrahydropyranyl, () Piperidinyl, () Morpholinyl, () Dithianyl (dithianyl), () Thiomorpholinyl, ()piperazinylidene or (trithianylidene)trithianyl.
- the groups also encompass bicyclic ring systems, including spiro, fused or bridged systems (such as 8-azaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2-nitrogen Heterobicyclo[2.2.2]octane, etc.).
- Heterocyclylene and heterocycle(radicals) may be optionally substituted with one or more (eg, 1, 2, 3, or 4) suitable substituents.
- the terms "()arylene” and "aromatic ring” refer to an all-carbon monocyclic or fused ring polycyclic aromatic group having a conjugated pi electron system.
- C 6-10 ()arylene” and “C 6-10 aromatic ring” mean an aromatic group containing 6 to 10 carbon atoms, such as ()phenylene (benzene ring) or ()naphthylene (naphthalene ring).
- the ()arylene and aromatic rings are optionally substituted with 1 or more (such as 1 to 3) suitable substituents (eg, halogen, -OH, -CN, -NO2 , C1-6 alkyl, etc.) .
- the ()arylene and aromatic rings are optionally fused with another ring (eg, a C 3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, or a 5-14 membered heteroaromatic ring), for example, the fused group is
- heteroarylidene and heteroaryl ring refer to monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms, and which contain at least one heteroatom (such as oxygen, nitrogen, etc.) which may be the same or different or sulfur) and, in addition, can be benzo-fused in each case.
- heteroatom such as oxygen, nitrogen, etc.
- "()heteroarylene” or “heteroaromatic ring” is selected from ()thienylene, ()furanyl, ()pyrrolylene, ()oxazolylylene, ()thiazolylylene, ()imidazolylidene, ()pyrazolylidene, ()isoxazolylidene, ()isothiazolylidene, ()oxadiazolylidene, ()triazolylidene, ()thiadiazolylidene etc., and their benzo derivatives; or ()pyridylene, ()pyridazinylene, ()pyrimidinylene, ()pyrazinylene, ()triazinylene, etc., and their benzos derivative.
- the "()heteroarylene” and “heteroaromatic ring” may also optionally be combined with another ring (eg, a C3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, a C6-10 aromatic ring, or a 5- 14-membered heteroaromatic ring) condensed, the condensed group is for example
- aralkyl preferably refers to an aryl or heteroaryl substituted alkyl group, wherein said aryl, heteroaryl and alkyl groups are as defined herein.
- the aryl group can have 6-14 carbon atoms
- the heteroaryl group can have 5-14 ring atoms
- the alkyl group can have 1-6 carbon atoms.
- Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.
- halo or halogen group is defined to include F, Cl, Br or I.
- substituted means that one or more (eg, one, two, three, or four) hydrogens on the designated atom are replaced by a selection from the designated group, provided that no more than the designated atom is present in the normal valences in the case and the substitutions form stable compounds. Combinations of substituents and/or variables are permissible only if such combinations form stable compounds.
- substituent can be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the list of substituents, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be independently and/or together independently Selected optional substituents are substituted. If a nitrogen of a substituent is described as being optionally substituted with one or more of the list of substituents, then one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be independently selected optional substitution of substituents.
- each substituent is selected independently of the other.
- each substituent may be the same as or different from another (other) substituent.
- one or more means 1 or more than 1, such as 2, 3, 4, 5 or 10, under reasonable conditions.
- the point of attachment of a substituent can be from any suitable position on the substituent.
- the present invention also includes all pharmaceutically acceptable isotopically-labeled compounds that are identical to the compounds of the present invention, except that one or more atoms have the same atomic number but an atomic mass or mass number different from the atomic mass that predominates in nature or atomic substitution of mass numbers.
- isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen (eg, deuterium (2H), tritium ( 3H )); isotopes of carbon (eg, 11C , 13C , and14C ) ; isotopes of chlorine (eg 36 Cl); isotopes of fluorine (eg 18 F); isotopes of iodine (eg 123 I and 125 I); isotopes of nitrogen (eg 13 N and 15 N); isotopes of oxygen (eg 15 O) , 17 O and 18 O); isotopes of phosphorus (eg 32 P); and isotopes of sulfur (eg 35 S).
- isotopes of hydrogen eg, deuterium (2H), tritium ( 3H )
- isotopes of carbon eg, 11C , 13C , and14C
- isotopes of chlorine eg 36
- Certain isotopically-labeled compounds of the invention are useful in drug and/or substrate tissue distribution studies (eg, assays).
- the radioisotopes tritium (ie 3 H) and carbon-14 (ie 14 C) are particularly useful for this purpose due to their ease of incorporation and ease of detection.
- Substitution with positron emitting isotopes such as11C , 18F , 15O , and13N can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies.
- Isotopically labeled compounds of the invention can be prepared by methods analogous to those described in the accompanying Schemes and/or Examples and Preparations by using an appropriate isotopically labeled reagent in place of the previously employed non-labeled reagent.
- Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent may be isotopically substituted, eg, D2O , acetone-d6, or DMSO - d6.
- stereoisomer refers to isomers formed due to at least one asymmetric center. In compounds having one or more (eg, one, two, three or four) asymmetric centers, it may give rise to racemic mixtures, single enantiomers, diastereomeric mixtures and individual of diastereomers. Certain individual molecules can also exist as geometric isomers (cis/trans). Similarly, the compounds of the present invention may exist as mixtures of two or more structurally distinct forms in rapid equilibrium (often referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers Wait. It is to be understood that the scope of this application covers all such in any ratio (eg 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% %) of isomers or mixtures thereof.
- Solid lines may be used in this article solid wedge or virtual wedge
- the chemical bonds of the compounds of the present invention are depicted.
- the use of a solid line to depict a bond to an asymmetric carbon atom is intended to indicate that all possible stereoisomers at that carbon atom are included (eg, a specific enantiomer, racemic mixture, etc.).
- the use of real or dashed wedges to delineate bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomer exists.
- real and imaginary wedges are used to define relative, rather than absolute, stereochemistry.
- the compounds of the present invention are intended to be available as stereoisomers (which include cis and trans isomers, optical isomers (eg, R and S enantiomers), diastereomers, Geometric isomers, rotational isomers, conformational isomers, atropisomers and mixtures thereof).
- stereoisomers which include cis and trans isomers, optical isomers (eg, R and S enantiomers), diastereomers, Geometric isomers, rotational isomers, conformational isomers, atropisomers and mixtures thereof).
- the compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (eg, racemic mixtures and pairs of diastereomers).
- the present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of more than one polymorph in any ratio.
- compositions of the present invention may exist in free form for use in therapy, or, where appropriate, in the form of their pharmaceutically acceptable derivatives.
- pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites or prodrugs which are administered to patients in need thereof After administration, the compounds of the invention or their metabolites or residues can be provided directly or indirectly. Accordingly, references herein to "compounds of the present invention" are also intended to encompass the various derivative forms of the compounds described above.
- Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
- Suitable acid addition salts are formed from acids which form pharmaceutically acceptable salts. Examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camphorsulphonate , citrate, cyclamate, ethanedisulfonate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate Salt, Hyphenate, Hydrochloride/Chloride, Hydrobromide/Bromide, Hydroiodide/Iodide, Isethionate, Lactate, Malate, Maleic Acid salt, malonate, mesylate, methyl sulfate, naphthylate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitic acid Salt, Pamoate, Phosphat
- Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts. Examples include aluminum salts, arginine salts, benzathine penicillin salts, calcium salts, choline salts, diethylamine salts, diethanolamine salts, glycinate salts, lysine salts, magnesium salts, meglumine salts, ethanolamine salts, Potassium, sodium, tromethamine and zinc salts.
- esters means an ester derived from each of the compounds of the general formula in this application, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release free acid or alcohol forms of the present invention) compound).
- the compounds of the present invention may themselves also be esters.
- the compounds of the present invention may exist in the form of solvates, preferably hydrates, wherein the compounds of the present invention comprise a polar solvent as a structural element of the crystal lattice of the compound, in particular for example water, methanol or ethanol.
- a polar solvent as a structural element of the crystal lattice of the compound, in particular for example water, methanol or ethanol.
- the amount of polar solvent, especially water, may be present in stoichiometric or non-stoichiometric ratios.
- Nitrogen-containing heterocycles are capable of forming N-oxides since nitrogen requires available lone pairs of electrons to oxidize to oxides; Nitrogen-containing heterocycles. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides.
- N-oxides of heterocycles and tertiary amines are well known to those skilled in the art and include the use of peroxyacids such as peracetic acid and m-chloroperoxybenzoic acid (MCPBA), hydrogen peroxide, alkyl Hydrogen peroxides such as t-butyl hydroperoxide, sodium perborate and dioxiranes such as dimethyldioxirane are used to oxidize heterocycles and tertiary amines.
- peroxyacids such as peracetic acid and m-chloroperoxybenzoic acid (MCPBA)
- hydrogen peroxide alkyl Hydrogen peroxides such as t-butyl hydroperoxide
- sodium perborate and dioxiranes such as dimethyldioxirane
- metabolites of the compounds of the present invention ie substances formed in the body upon administration of the compounds of the present invention. Such products may result from, for example, oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, and the like, of the administered compound.
- the present invention includes metabolites of the compounds of the present invention, including compounds prepared by methods of contacting a compound of the present invention with a mammal for a time sufficient to produce the metabolites thereof.
- the present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity when administered into or onto the body can be converted into compounds of the invention having the desired activity, for example, by hydrolytic cleavage.
- prodrugs will be functional derivatives of the compound that are readily converted in vivo to the desired therapeutically active compound. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella).
- prodrugs of the present invention can be obtained, for example, by using certain moieties known to those skilled in the art as “pro-moiety (eg as described in “Design of Prodrugs", H. Bundgaard (Elsevier, 1985))" Prepared by substituting appropriate functional groups present in the compounds of the present invention.
- the present invention also encompasses compounds of the present invention that contain protecting groups.
- protecting groups In any process for preparing the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any relevant molecule, thereby forming chemically protected forms of the compounds of the present invention. This can be accomplished with conventional protecting groups, such as those described in T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (I):
- R 5 and R 6 at each occurrence are each independently selected from H, C 1-6 alkyl, C 3-10 cyclohydrocarbyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered Heteroaryl and C 6-12 aralkyl; and
- n is an integer selected from 0, 1, 2, 3 and 4.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (II):
- Ring A is and
- n is an integer selected from 0, 1, 2 or 3.
- -LR 2 is selected from
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein ring B is a bicyclo[1.1.1]pentane ring, a 2-oxabicyclo[2.1.1]hexane ring, a benzene ring or a thiophene ring, most preferably a benzene ring or a thiophene ring.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein each occurrence of R 1 is independently selected from halogen, -NH 2 , C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1 -6 alkylene-OH, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10 membered heterocyclyl, C 6-10 aryl and 5-14 membered heteroaryl,
- the alkylene, alkyl, cyclohydrocarbyl, heterocyclyl, aryl, and heteroaryl groups are optionally one or more independently selected from halogen, -OH, C 3-6 cyclohydrocarbyl, 3-10 membered Substituent substitution of heterocyclyl, C 6-10 aryl
- each occurrence of R 1 is independently selected from CF 3 , NH 2 , And m is 1 or 2.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof ,in selected from
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein R 3 is selected from H and C 1-6 alkyl; preferably, R 3 is methyl.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein R 4 is selected from H and C 1-6 alkyl; preferably, R 4 is H.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (III):
- the present invention encompasses compounds resulting from any combination of the various embodiments.
- the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound is selected from:
- compositions and methods of treatment are provided.
- the present invention provides pharmaceutical compositions comprising a prophylactically or therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate,
- a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate The N-oxide, isotope-labeled compound, metabolite or prodrug and one or more pharmaceutically acceptable carriers, the pharmaceutical composition is preferably a solid preparation, semi-solid preparation, liquid preparation or gaseous preparation.
- the pharmaceutical composition may further comprise one or more other therapeutic agents.
- the present invention provides compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites thereof Or prodrug or use of the pharmaceutical composition of the present invention in the preparation of a medicament for use as an inhibitor of SOS1.
- the present invention provides compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites thereof or a prodrug or a pharmaceutical composition of the present invention, which acts as a SOS1 inhibitor.
- the present invention provides a method of preventing or treating an SOS1-related disease, the method comprising administering to an individual in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer thereof body, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug or pharmaceutical composition of the present invention.
- the SOS1-related disease includes cancer (eg, pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid Leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate carcinoma, glioblastoma, renal carcinoma, and sarcoma), RAS disorders (eg, neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Noonan syndrome with multiple spots (NSML), capillary Vascular malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facial-cutaneous syndrome (CFC), Leggers syndrome and hereditary gingival fibr
- cancer
- “Pharmaceutically acceptable carrier” refers to a diluent, adjuvant, excipient or vehicle with which the therapeutic agent is administered and which, within the scope of sound medical judgment, is suitable for contact with humans and/or tissue from other animals without undue toxicity, irritation, allergic reactions, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral Oil, sesame oil, etc. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously.
- sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral Oil, sesame oil, etc.
- Water is an exemplary carrier when the pharmaceutical composition is administered intravenously.
- Physiological saline and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, nonfat dry milk, glycerin, propylene glycol, water, Ethanol etc.
- the composition may also contain minor amounts of wetting agents, emulsifying agents or pH buffering agents as desired.
- Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
- compositions of the present invention may act systemically and/or locally.
- they may be administered by a suitable route, for example by injection (eg intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including instillation) or transdermally; or by oral, buccal, transdermal Nasal, transmucosal, topical, in ophthalmic formulations or by inhalation.
- compositions of the present invention may be administered in suitable dosage forms.
- Such dosage forms include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions , injectable solutions, elixirs, syrups.
- an effective amount refers to the amount of a compound which, when administered, will alleviate to some extent one or more symptoms of the condition being treated.
- Dosage regimens can be adjusted to provide the optimal desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is further understood that for any particular individual, the specific dosing regimen should be adjusted over time according to the needs of the individual and the professional judgment of the person administering or supervising the administration of the composition.
- the amount of the compound of the invention administered will depend on the individual being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound, and the judgment of the prescribing physician. In general, an effective dose will range from about 0.0001 to about 50 mg per kg of body weight per day, eg, from about 0.01 to about 10 mg/kg/day (single or divided administration). For a 70 kg person, this would add up to about 0.007 mg/day to about 3500 mg/day, eg, about 0.7 mg/day to about 700 mg/day.
- dose levels not higher than the lower end of the foregoing ranges may be sufficient, while in other cases larger doses may be employed without causing any deleterious side effects, provided that the larger dose is first
- the dose is divided into several smaller doses to be administered throughout the day.
- the content or amount of the compound of the present invention in the pharmaceutical composition may be about 0.01 mg to about 1000 mg, suitably 0.1-500 mg, preferably 0.5-300 mg, more preferably 1-150 mg, particularly preferably 1-50 mg, such as 1.5 mg, 2mg, 4mg, 10mg, 25mg, etc.
- treating means reversing, alleviating, inhibiting the progression of the disorder or condition to which such term applies or one or more symptoms of such disorder or condition, or Such a disorder or condition or one or more symptoms of such a disorder or condition is prevented.
- an “individual” as used herein includes a human or non-human animal.
- exemplary human subjects include human subjects (referred to as patients) or normal subjects with a disease (eg, a disease described herein).
- Non-human animals in the present invention include all vertebrates such as non-mammals (eg birds, amphibians, reptiles) and mammals such as non-human primates, livestock and/or domesticated animals (eg sheep, dogs) , cats, cows, pigs, etc.).
- compositions of the present invention may further comprise one or more additional therapeutic or prophylactic agents.
- Thin-layer chromatography was performed using Huanghai brand HSGF 254 (5 ⁇ 20em) silica gel plates, and thin-layer preparative chromatography was performed using GF 254 (0.4-0.5nm) silica plates produced in Yantai.
- reaction was detected by thin layer chromatography (TLC) or LC-MS, and the developing solvent systems used included dichloromethane and methanol system, n-hexane and ethyl acetate system, and petroleum ether and ethyl acetate system. Different polarities adjust the developing agent system (by adjusting the volume ratio of the solvent or adding triethylamine, etc.).
- BiotageInitiator+ 400W, RT ⁇ 300°C microwave reactor was used.
- the eluent system includes dichloromethane and methanol system and n-hexane and ethyl acetate system, and the eluent system is adjusted according to the polarity of the compound to be separated (by adjusting the volume ratio of the solvent or adding triethylamine, etc. conduct).
- reaction temperature is room temperature (20°C to 30°C).
- the reagents used in the examples were purchased from companies such as Acros Organics, Aldrich Chemical Company or Shanghai Bide Pharmaceutical Technology Co., Ltd.
- Step 1 Dissolve acetamidine (2.4 g, 23.1 mmol) in methanol (50 mL), add sodium methoxide (3.2 g, 58.4 mmol) and 1-(tert-butyl) 3-methyl 4-oxopiperidine -1,3-Dicarboxylate (5.0 g, 19.5 mmol). The reaction solution was stirred at 60°C for 6 hours.
- the third step Dissolve 301-2 (2.0 g, 7.1 mmol) in dimethyl sulfoxide (20 mL), add (R)-1-(3-nitro-5-(trifluoromethyl)phenyl) Ethan-1-amine hydrochloride (2.3 g, 8.5 mmol) and N,N-diisopropylethylamine (2.7 g, 21.3 mmol), and the reaction solution was stirred at 150° C. for 16 hours.
- the fourth step: 301-3 (1.7g, 3.5mmol) was dissolved in dioxane (20mL), hydrochloric acid (4M, solution in dioxane) (5mL) was added, and the reaction solution was stirred at room temperature, The reaction of the raw materials was monitored by TLC, and the solvent was removed by concentration under reduced pressure to obtain compound 301-4 (1.3 g), which was a white solid with a yield of 90%.
- the fifth step dissolve 301-4 (150mg, 0.4mmol) in methanol (5mL), add cyclobutanone (50mg, 0.7mmol), anhydrous zinc chloride (145mg, 1.0mmol) and sodium cyanoborohydride ( 68 mg, 1.0 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 301-5 (120 mg) as a yellow solid with a yield of 76%.
- Step 6 Dissolve 301-5 (120mg, 0.3mmol) in ethanol (5mL) and water (2mL), add iron powder (157mg, 2.8mmol) and ammonium chloride (150mg, 2.8mmol), put the reaction solution in Stir at 90°C for 2 hours.
- the first step dissolve 301-4 (130mg, 0.3mmol) in methanol (5mL), add tetrahydro-4H-pyran-4-one (60mg, 0.6mmol), anhydrous zinc chloride (121mg, 0.9mmol) ) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction solution was stirred at room temperature for 15 hours.
- the reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 302-1 (110 mg) as a yellow solid with a yield of 76%.
- Step 2 Dissolve 302-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours.
- the first step Compound 301-2 (2.0 g, 7.1 mmol) was dissolved in dimethyl sulfoxide (20 mL), and (R)-1-(5-bromothiophen-2-yl) ethan-1-amine salt was added acid (2.0 g, 8.5 mmol) and N,N-diisopropylethylamine (2.7 g, 21.3 mmol), and the reaction solution was stirred at 150° C. for 16 hours.
- Step 2 Dissolve 303-1 (1.7g, 3.8mmol) in dioxane ⁇ water (5:1) (30mL), add (2-((dimethylamino)methyl)phenyl)boronic acid (1.0 g, 5.7 mmol), tetrakis(triphenylphosphine)palladium (462 mg, 0.4 mmol) and potassium carbonate (1.6 g, 11.4 mmol), and the reaction solution was stirred at 100° C. for 16 hours.
- the third step Dissolve 303-2 (1.7 g, 3.0 mmol) in dioxane (20 mL), add hydrochloric acid (4M, a solution in dioxane) (5 mL), and stir the reaction solution at room temperature. TLC After monitoring the reaction of the raw materials, the solvent was removed by concentration under reduced pressure to obtain compound 303-3 (1.0 g) as a white solid with a yield of 83%.
- ESI-MS 408[M+H] + .
- the fourth step dissolve 303-3 (120mg, 0.3mmol) in methanol (5mL), add cyclobutanone (43mg, 0.6mmol), anhydrous zinc chloride (130mg, 0.9mmol) and sodium cyanoborohydride ( 61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours.
- the first step Dissolve 301-4 (130 mg, 0.3 mmol) in methanol (5 mL), add N,N-dimethyl-4-oxocyclohexane-1-carboxamide (101 mg, 0.6 mmol), no Aqueous zinc chloride (121 mg, 0.9 mmol) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 304-1 (110 mg) as a yellow solid with a yield of 69%.
- ESI-MS 535[M+H] + .
- Step 2 Dissolve 304-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours.
- the first step Compound 301-4 (130 mg, 0.3 mmol) was dissolved in methanol (5 mL), 1-acetylpiperidin-4-one (85 mg, 0.6 mmol), anhydrous zinc chloride (121 mg, 0.9 mmol) were added ) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction solution was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 306-1 (130 mg) as a yellow solid with a yield of 86%.
- ESI-MS 507[M+H] + .
- Step 2 Dissolve 306-1 (130mg, 0.3mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours.
- Step 1 Dissolve tetrahydro-2H-pyridine-4-carboxylic acid (40 mg, 0.9 mmol) in N,N-dimethylformamide (3 mL), add HATU (137 mg, 0.4 mmol), N,N - Diisopropylethylamine (116 mg, 0.9 mmol) and compound 301-4 (130 mg, 0.3 mmol), the reaction solution was stirred at room temperature for 15 hours. It was diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 308-1 (110 mg) as a yellow solid with a yield of 74%.
- Step 2 Dissolve 308-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours.
- Tetrahydro-2H-pyran-4-carboxylic acid (40 mg, 0.9 mmol) was dissolved in N,N-dimethylformamide (3 mL), HATU (137 mg, 0.4 mmol), N,N-diisopropyl were added Ethylamine (116 mg, 0.9 mmol) and compound 303-3 (100 mg, 0.3 mmol), the reaction solution was stirred at room temperature for 15 hours.
- the first step Compound 301-4 (130 mg, 0.3 mmol) was dissolved in methanol (5 mL), tetrahydro-2H-pyran-4-carbaldehyde (68 mg, 0.6 mmol), anhydrous zinc chloride (121 mg, 0.9 mmol) were added mmol) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2 ⁇ 20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 310-1 (110 mg) as a yellow solid with a yield of 76%.
- Step 2 Dissolve 310-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours.
- the first step Compound 301-2 (1.0 g, 3.5 mmol) was dissolved in dimethyl sulfoxide (20 mL), and (R)-1-(4-bromothiophen-2-yl) ethan-1-amine salt was added acid (1.0 g, 4.2 mmol) and N,N-diisopropylethylamine (1.4 g, 10.2 mmol), and the reaction solution was stirred at 150° C. for 16 hours.
- Step 2 Dissolve 312-1 (900 mg, 2.0 mmol) in dioxane ⁇ water (5:1) (15 mL), add (2-((dimethylamino)methyl)phenyl)boronic acid ( 534 mg, 3.0 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 0.2 mmol) and potassium carbonate (823 mg, 6.0 mmol), and the reaction solution was stirred at 100°C for 16 hours.
- the third step Dissolve 312-2 (450 mg, 0.9 mmol) in dioxane (5 mL), add hydrochloric acid (4M, a solution in dioxane) (3 mL), and stir the reaction solution at room temperature. TLC After monitoring the completion of the reaction of the raw materials, the solvent was removed by concentration under reduced pressure to obtain compound 312-3 (300 mg) as a white solid with a yield of 82%.
- ESI-MS 408[M+H] + .
- the fourth step dissolve 312-3 (100mg, 0.3mmol) in methanol (5mL), add 1-acetylpiperidin-4-one (71mg, 0.5mmol), anhydrous zinc chloride (116mg, 0.8mmol) and sodium cyanoborohydride (54 mg, 0.8 mmol), and the reaction was stirred at room temperature for 15 hours.
- This assay can be used to examine the potency of compounds to inhibit the protein-protein interaction between SOS1 and KRAS G12C . This demonstrates the molecular mode of action of the compound. Low IC50 values indicate high potency of the SOS1 inhibitor compound in this assay setup below.
- Assay Plate ProxiPlate-384Plus, purchased from PerkinElmer (Cat. No. 6008280)
- Assay buffer PPI, purchased from Cisbio (Cat. No. 61DB10RDF)
- Dissolve the compound to be tested in DMSO prepare a stock solution with a concentration of 10 mM, and dilute the compound concentration with DMSO to 2 mM as the starting concentration of the assay, serially dilute the compound solution with a 2 mM starting concentration 3 times, and dilute a total of 10 concentrations, using Labcyte
- the Echo instrument transferred 0.1 ⁇ L of compound solutions of each concentration to a 384-well assay plate (duplicate, double wells);
- Each plate contains the following controls:
- IC50 values were calculated and analyzed using a 4-parameter regression equation. The measurement results are shown in the table below.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An SOS1 inhibitor as in formula (I), a pharmaceutical composition containing same, and a use therefor in preventing or treating diseases.
Description
本发明涉及SOS1抑制剂、包含其的药物组合物、及其用于预防或治疗疾病的用途。The present invention relates to SOS1 inhibitors, pharmaceutical compositions containing them, and their use for preventing or treating diseases.
发明背景Background of the Invention
RAS家族蛋白是由RAS基因编码的小GTP酶,包括KRAS(Kirsten鼠肉瘤病毒致癌基因同源物)、HRAS(Harvey鼠肉瘤病毒致癌基因)和NRAS(神经母细胞瘤RAS病毒致癌基因同源物)及其任何突变体。在细胞内,RAS蛋白在失活和激活状态之间转变,当与鸟嘌呤核苷二磷酸(GDP)结合时,RAS蛋白处于失活状态,当与鸟嘌呤核苷三磷酸(GTP)结合时,RAS蛋白被激活。RAS蛋白的固有GTP酶活性较弱,且内在的GDP-GTP核苷酸交换速率较低,其失活与激活状态之间的转换受到两类因子的调节:GTP酶激活蛋白(GTPase activating protein,GAP),可催化与RAS蛋白结合的GTP水解为GDP,使RAS蛋白失活;鸟嘌呤核苷酸交换因子(Guanine nucleotide exchange factor,GEF),包括SOS1蛋白(Son of Sevenless 1)等,可催化RAS蛋白与GTP的结合,从而促进RAS蛋白的激活。激活状态下的RAS蛋白可通过激活一系列下游效应蛋白(包括RAF和磷脂酰肌醇激酶PI3K等)来激活RAF/MEK/ERK(MAPK)通路和PI3K/AKT/mTOR通路等多条信号转导通路,从而调控细胞增殖、存活、代谢、运动、血管生成、免疫和生长等多种细胞过程。RAS家族蛋白突变可抑制其固有GTP酶活性和GAP诱导的GTP酶活性,导致RAS蛋白的持续激活,进而导致RAS蛋白下游效应通路的持续激活。RAS是人类癌症中最常出现突变的致癌基因,KRAS突变(如G12、G13和Q61等)广泛存在于包括肺癌、结直肠癌和胰腺癌等多种人类癌症中,HRAS突变和NRAS突变同样出现在不同人类癌症类型中。RAS蛋白突变、过表达及基因扩增是针对多种抗癌药物(如EGFR抗体西妥昔单抗和帕尼单抗、EGFR酪氨酸激酶抑制剂奥希替尼)的潜在耐药机制。RAS family proteins are small GTPases encoded by the RAS gene, including KRAS (Kirsten murine sarcoma virus oncogene homolog), HRAS (Harvey murine sarcoma virus oncogene) and NRAS (neuroblastoma RAS virus oncogene homolog) ) and any mutants thereof. Inside the cell, RAS proteins transition between inactive and activated states. When bound to guanosine diphosphate (GDP), RAS proteins are in an inactive state and when bound to guanosine triphosphate (GTP) , RAS protein is activated. The intrinsic GTPase activity of RAS protein is weak, and the intrinsic GDP-GTP nucleotide exchange rate is low, and the transition between its inactivation and activation states is regulated by two types of factors: GTPase activating protein (GTPase activating protein, GAP), which can catalyze the hydrolysis of GTP bound to RAS protein to GDP, inactivating RAS protein; Guanine nucleotide exchange factor (GEF), including SOS1 protein (Son of Sevenless 1), etc., can catalyze the Binding of RAS protein to GTP, thereby promoting the activation of RAS protein. Activated RAS protein can activate multiple signal transductions such as RAF/MEK/ERK (MAPK) pathway and PI3K/AKT/mTOR pathway by activating a series of downstream effector proteins (including RAF and phosphatidylinositol kinase PI3K, etc.) pathways, thereby regulating a variety of cellular processes such as cell proliferation, survival, metabolism, motility, angiogenesis, immunity, and growth. Mutation of RAS family proteins can inhibit their intrinsic GTPase activity and GAP-induced GTPase activity, resulting in persistent activation of RAS proteins, which in turn leads to persistent activation of downstream effector pathways of RAS proteins. RAS is the most frequently mutated oncogene in human cancers. KRAS mutations (such as G12, G13, and Q61, etc.) are widely present in a variety of human cancers, including lung, colorectal, and pancreatic cancer. HRAS mutations and NRAS mutations also occur. in different human cancer types. Mutation, overexpression and gene amplification of RAS protein are potential mechanisms of resistance to various anticancer drugs (eg, EGFR antibodies cetuximab and panitumumab, EGFR tyrosine kinase inhibitor osimertinib).
SOS蛋白最早发现于果蝇中,SOS1是果绳SOS蛋白的人类同源物。SOS1蛋白是由1333个氨基酸组成的多结构域蛋白,由N-末端结构域、Dbl同源结构域(Dbl homology,DH)、Pleckstrin底物蛋白同源结构域(Pleckstrin homology,PH)、RAS交换基序(Ras exchanger motif,REM)、CDC25同源结构域和C-末端结构域构成,其中REM和CDC25同源结构域共同组成催化功能域,是SOS1蛋白发挥鸟嘌呤核苷酸交换因子催化功能的必须部分。研究表明SOS1在RAS突变的癌症中对突变型RAS蛋白的激活和信号转导具有关键作用,SOS1敲除会抑制KRAS突变肿瘤细胞的存活和增殖,在SOS1敲除的KRAS突变肿瘤细胞中重新表达催化位点突变型SOS1,肿瘤细胞无法恢复存活和增殖,证明SOS1的鸟嘌呤核苷酸交换催化活性对KRAS突变肿瘤细胞的存活和增殖具有关键作用。除了调控突变型RAS蛋白,SOS1也可通过其它机制参与肿瘤细胞的信号激活与传导过程。SOS1可结合生长因子受体结合蛋白Grb2形成SOS1-Grb2复合物,进而结合活化的受体酪氨酸激酶(如EGFR、ErbB2/3/4、VEGFR1/2/3、PDGFR-A/B、FGFR1/2/3、IGF1R、ALK、ROS1、TRK-A/B/C、RET、c-MET、AXL等),或者被其他细胞表面的膜受体(如TCR、BCR、CSF1R)所募集。SOS1可作为鸟嘌呤核苷酸交换因子激活GTP酶RAC1,RAC1与多种人类癌症及其他疾病相关。研究表明,SOS1突变存在于胚胎性横纹肌肉瘤、睾丸支持细胞瘤、皮肤颗粒细胞瘤和肺腺癌中,在膀胱癌和前列腺癌中也发现了SOS1蛋白的过表达。The SOS protein was first discovered in Drosophila, and SOS1 is the human homolog of the Drosophila SOS protein. SOS1 protein is a multi-domain protein composed of 1333 amino acids, consisting of N-terminal domain, Dbl homology domain (Dbl homology, DH), Pleckstrin substrate protein homology domain (Pleckstrin homology, PH), RAS exchange Motif (Ras exchanger motif, REM), CDC25 homology domain and C-terminal domain, among which REM and CDC25 homology domain together form a catalytic domain, which is the catalytic function of SOS1 protein to play a guanine nucleotide exchange factor the required part. Studies have shown that SOS1 has a critical role in the activation and signaling of mutant RAS proteins in RAS-mutant cancers, and SOS1 knockout inhibits the survival and proliferation of KRAS-mutant tumor cells, and is re-expressed in SOS1-knockout KRAS-mutant tumor cells Catalytic site mutant SOS1, tumor cells could not restore survival and proliferation, demonstrating that the guanine nucleotide exchange catalytic activity of SOS1 is critical for the survival and proliferation of KRAS mutant tumor cells. In addition to regulating mutant RAS proteins, SOS1 can also participate in the signal activation and transduction process of tumor cells through other mechanisms. SOS1 can bind to growth factor receptor-binding protein Grb2 to form a SOS1-Grb2 complex, which in turn binds to activated receptor tyrosine kinases (such as EGFR, ErbB2/3/4, VEGFR1/2/3, PDGFR-A/B, FGFR1 /2/3, IGF1R, ALK, ROS1, TRK-A/B/C, RET, c-MET, AXL, etc.), or recruited by other cell surface membrane receptors (such as TCR, BCR, CSF1R). SOS1 acts as a guanine nucleotide exchange factor to activate the GTPase RAC1, which is associated with a variety of human cancers and other diseases. Studies have shown that SOS1 mutations are present in embryonal rhabdomyosarcoma, Sertolioma, cutaneous granulosa cell tumor, and lung adenocarcinoma, and overexpression of the SOS1 protein has also been found in bladder and prostate cancers.
SOS2是哺乳动物细胞中SOS1的同源物,同样具有鸟嘌呤核苷酸交换因子功能。小鼠基因敲除模型研究表明,SOS1种系敲除可导致小鼠胚胎在妊娠中期死亡,而成年小鼠在SOS1敲除后可继续存活,相比之下,SOS2敲除对胚胎及成熟小鼠均无任何明显的表型变化,而SOS1/2双敲除的成年小鼠会迅速死亡,这表明对于受到SOS1调控的RAS突变肿瘤,选择性靶向SOS1可能会实现较高的治疗指数。SOS2 is a homologue of SOS1 in mammalian cells and also functions as a guanine nucleotide exchange factor. Mouse knockout model studies have shown that germline knockout of SOS1 can lead to the death of mouse embryos in the second trimester, while adult mice continue to survive after knockout of SOS1. None of the mice exhibited any apparent phenotypic changes, while adult mice with SOS1/2 double knockout died rapidly, suggesting that selective targeting of SOS1 may achieve a high therapeutic index for SOS1-regulated RAS-mutant tumors.
抑制SOS1催化位点与RAS蛋白结合可阻断SOS1介导的RAS蛋白激活,进而抑制RAS蛋白下游信号传导(如ERK的磷酸化激活等),具有此类作用机制的SOS1抑制剂对突变型RAS蛋白依赖的肿瘤细胞如KRAS突变肿瘤细胞系具有抑制作用(如抑制增殖、存活、转移等)。Inhibiting the binding of SOS1 catalytic site to RAS protein can block SOS1-mediated RAS protein activation, thereby inhibiting RAS protein downstream signaling (such as ERK phosphorylation activation, etc.). SOS1 inhibitors with such a mechanism of action can inhibit mutant RAS. Protein-dependent tumor cells such as KRAS mutant tumor cell lines have inhibitory effects (eg, inhibition of proliferation, survival, metastasis, etc.).
发明概述SUMMARY OF THE INVENTION
本发明提供用作SOS1抑制剂的化合物,其具有对SOS1的优异的抑制活性。本发明的SOS1抑制剂可抑制SOS1与RAS蛋白的相互作用及激活,尤其是对SOS1和KRAS突变蛋白相互作用具有 显著的抑制作用,可为携带RAS及上下游蛋白(包括KRAS、NRAS、HRAS、受体酪氨酸激酶(如EGFR、ErbB2/3/4、PDGFR-A/B、FGFR1/2/3、IGF1R、INSR、ALK、ROS、TrkA/B/C、RET、c-MET、VEGFR1/2/3、AXL)、GAP(如NF1)和SOS1)突变的癌症患者提供药理学益处。此外,SOS1抑制剂在RAC1依赖性的癌症及RAS信号通路失调相关的其他疾病如神经纤维瘤、努南综合征(NS)、心-面-皮肤综合征(CFC)和1型遗传性牙龈纤维瘤中也将提供药理学益处。The present invention provides compounds useful as SOS1 inhibitors, which have excellent inhibitory activity against SOS1. The SOS1 inhibitor of the present invention can inhibit the interaction and activation of SOS1 and RAS protein, especially has a significant inhibitory effect on the interaction between SOS1 and KRAS mutant protein, and can be used for carrying RAS and upstream and downstream proteins (including KRAS, NRAS, HRAS, Receptor tyrosine kinases (eg EGFR, ErbB2/3/4, PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA/B/C, RET, c-MET, VEGFR1/ 2/3, AXL), GAP (eg, NF1) and SOS1) mutated cancer patients provide pharmacological benefit. In addition, SOS1 inhibitors in RAC1-dependent cancers and other diseases associated with dysregulation of RAS signaling pathway such as neurofibromas, Noonan syndrome (NS), cardio-facial-cutaneous syndrome (CFC) and hereditary gingival fibrosis type 1 Pharmacological benefits will also be provided in tumors.
本发明的化合物还具有更好的物理化学性质(例如溶解度、物理和/或化学稳定性)、改善的药物代谢动力学性质(例如改善的生物利用度、合适的半衰期和作用持续时间)、改善的安全性(较低的毒性和/或较少的副作用,较宽的治疗窗)等更优异的性质。The compounds of the invention also have better physicochemical properties (eg solubility, physical and/or chemical stability), improved pharmacokinetic properties (eg improved bioavailability, suitable half-life and duration of action), improved safety (lower toxicity and/or fewer side effects, wider therapeutic window) and other more excellent properties.
本发明的一个方面提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(I)的结构:One aspect of the present invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the Said compound has the structure of formula (I):
其中:in:
X
1、X
2、X
3和X
4各自独立地选自C=O、CH
2、CHR、C(R)
2和N-L-R
2,优选地,X
1、X
2、X
3和X
4中至少一个为N-L-R
2;
X 1 , X 2 , X 3 and X 4 are each independently selected from C=O, CH 2 , CHR, C(R) 2 and NLR 2 , preferably, at least among X 1 , X 2 , X 3 and X 4 One is NLR 2 ;
L选自直接键、C
1-6亚烷基、C(=O)、O、S(=O)、S(=O)
2和NR
4;
L is selected from direct bond, C1-6 alkylene, C(=O), O, S(=O), S(=O) 2 and NR4 ;
环B选自C
3-10烃环、3-10元杂环、C
6-10芳环和5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O);
Ring B is selected from C 3-10 hydrocarbon rings, 3-10-membered heterocycles, C 6-10 -membered aromatic rings and 5-14-membered heteroaromatic rings, wherein at most 2 ring members of the hydrocarbon rings and heterocycles are C(= O);
R和R
1在每次出现时各自独立地选自卤素、-NH
2、-CN、-NO
2、-OH、-O-C
1-6烷基、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基和C
6-12芳烷基,所述环烃基和杂环基中至多2个环成员为C(=O),当m大于1和/或n大于1时,两个R
1和/或两个R连同其所连接的原子任选地共同构成C
3-10烃环、3-10元杂环、C
6-10芳环或5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O);
R and R 1 are each independently selected at each occurrence from halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, C 1-6 alkyl, halogenated C 1- 6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl, saturated or partially unsaturated C 3-10 Cyclic hydrocarbon groups, saturated or partially unsaturated 3-10 membered heterocyclic groups, C 6-10 aryl groups, 5-14 membered heteroaryl groups and C 6-12 aralkyl groups, among the cyclic hydrocarbon groups and heterocyclic groups at most 2 ring members are C(=O), when m is greater than 1 and/or n is greater than 1, two R 1 and/or two R together with the atoms to which they are attached optionally together form a C 3-10 hydrocarbon ring , 3-10-membered heterocyclic ring, C 6-10 -membered aromatic ring or 5-14-membered heteroaromatic ring, wherein at most 2 ring members in the hydrocarbon ring and the heterocyclic ring are C(=O);
R
2选自H、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6、-C
1-6亚烷基-O(P=O)(OH)
2和-O-C
1-6亚烷基-NR
5R
6;
R 2 is selected from H, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl , C 2-6 alkynyl, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl, -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O) R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 sub Alkyl-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;
R
3和R
4各自独立地选自H、卤素、-NH
2、-CN、-NO
2、-OH、-O-C
1-6烷基、-O-(3-10元杂环基)、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6、-C
1-6亚烷基-O(P=O)(OH)
2和-O-C
1-6亚烷基-NR
5R
6;
R 3 and R 4 are each independently selected from H, halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, -O-(3-10 membered heterocyclyl), C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl , saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl group , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O ) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 - C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;
上述基团在每次出现时各自任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH
2、-CN、-NO
2、C
1-6烷基、C
2-6烯基、C
2-6炔基、C
3-6环烃基、3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、=N-OR
5、-C(=NH)NH
2、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6和-O-C
1-6亚烷基-NR
5R
6,所述烷基、环烃基、杂环基、芳基、杂芳基和芳烷基进一步任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH
2、-CN、-NO
2、C
1-6烷基、C
3-6环烃基、3-10元杂环基、C
6-10芳基、5-14元杂芳基和C
6-12芳烷基;
The above groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, -NH2 , -CN, -NO2 , C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered heteroaryl, C 6- 12 Aralkyl, =N-OR 5 , -C(=NH)NH 2 , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O) -NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 and -OC 1-6 alkylene-NR 5 R 6 , the alkyl, cyclohydrocarbyl, heterocyclyl, aryl, heterocyclyl Aryl and aralkyl are further optionally substituted with one or more substituents independently selected from halogen, -OH, oxo, -NH2 , -CN, -NO2 , Ci_6alkyl , C 3-6 cyclic hydrocarbon group, 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group and C 6-12 aralkyl group;
R
5和R
6在每次出现时各自独立地选自H、C
1-6烷基、C
3-10环烃基、3-10元杂环基、C
6-10芳基、 5-14元杂芳基和C
6-12芳烷基;并且
R 5 and R 6 at each occurrence are each independently selected from H, C 1-6 alkyl, C 3-10 cyclohydrocarbyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered Heteroaryl and C 6-12 aralkyl; and
m为选自0、1、2、3和4的整数。m is an integer selected from 0, 1, 2, 3 and 4.
本发明的另一方面提供药物组合物,其包含预防或治疗有效量的本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药以及一种或多种药学上可接受的载体,所述药物组合物优选为固体制剂、半固体制剂、液体制剂或气态制剂。Another aspect of the present invention provides pharmaceutical compositions comprising a prophylactically or therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N- Oxides, isotopically-labeled compounds, metabolites or prodrugs and one or more pharmaceutically acceptable carriers, the pharmaceutical composition is preferably a solid preparation, semi-solid preparation, liquid preparation or gaseous preparation.
本发明的另一方面提供本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物在制备用作SOS1抑制剂的药物中的用途。Another aspect of the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro- Use of the medicament or the pharmaceutical composition of the present invention in the preparation of a medicament for use as an SOS1 inhibitor.
本发明的另一方面提供本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物,其用作SOS1抑制剂。Another aspect of the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro- A drug or a pharmaceutical composition of the present invention for use as an SOS1 inhibitor.
本发明的另一方面提供预防或治疗SOS1相关疾病的方法,所述方法包括向需要其的个体给药有效量的本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物。Another aspect of the present invention provides a method of preventing or treating SOS1-related diseases, the method comprising administering to an individual in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, Polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs or pharmaceutical compositions of the invention.
发明详述Detailed description of the invention
定义definition
除非在下文中另有定义,本文中所用的所有技术术语和科学术语的含义意图与本领域技术人员通常所理解的相同。提及本文中使用的技术意图指在本领域中通常所理解的技术,包括那些对本领域技术人员显而易见的技术的变化或等效技术的替换。虽然相信以下术语对于本领域技术人员很好理解,但仍然阐述以下定义以更好地解释本发明。Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art. References to techniques used herein are intended to refer to techniques commonly understood in the art, including those variations or substitutions of equivalent techniques that would be apparent to those skilled in the art. While the following terms are believed to be well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.
术语“包括”、“包含”、“具有”、“含有”或“涉及”及其在本文中的其它变体形式为包含性的(inclusive)或开放式的,且不排除其它未列举的元素或方法步骤。The terms "comprising", "comprising", "having", "containing" or "involving" and other variations thereof herein are inclusive or open ended and do not exclude other unrecited elements or method steps.
如本文中所使用,术语“亚烷基”表示饱和二价烃基,优选表示具有1、2、3、4、5或6个碳原子的饱和二价烃基,例如亚甲基、亚乙基、亚丙基或亚丁基。As used herein, the term "alkylene" refers to a saturated divalent hydrocarbon radical, preferably a saturated divalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
如本文中所使用,术语“烷基”定义为线性或支化饱和脂肪族烃。在一些实施方案中,烷基具有1至12个,例如1至6个碳原子。例如,如本文中所使用,术语“C
1-6烷基”指1至6个碳原子的线性或支化的基团(例如甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基或正己基),其任选地被1或多个(诸如1至3个)适合的取代基如卤素取代(此时该基团被称作“卤代烷基”)(例如CH
2F、CHF
2、CF
3、CCl
3、C
2F
5、C
2Cl
5、CH
2CF
3、CH
2Cl或-CH
2CH
2CF
3等)。术语“C
1-4烷基”指1至4个碳原子的线性或支化的脂肪族烃链(即甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基)。
As used herein, the term "alkyl" is defined as a linear or branched saturated aliphatic hydrocarbon. In some embodiments, the alkyl group has 1 to 12, eg, 1 to 6, carbon atoms. For example, as used herein, the term "C 1-6 alkyl" refers to a linear or branched group of 1 to 6 carbon atoms (eg, methyl, ethyl, n-propyl, isopropyl, n-butyl) , isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl) optionally substituted by 1 or more (such as 1 to 3) suitable substituents Such as halogen substituted (where the group is referred to as "haloalkyl" ) ( eg CH2F , CHF2 , CF3 , CCl3 , C2F5 , C2Cl5 , CH2CF3 , CH2Cl or -CH 2 CH 2 CF 3 , etc.). The term "C 1-4 alkyl" refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
如本文中所使用,术语“烯基”意指线性的或支化的单价烃基,其包含一个双键,且具有2-6个碳原子(“C
2-6烯基”)。所述烯基为例如乙烯基、1-丙烯基、2-丙烯基、2-丁烯基、3-丁烯基、2-戊烯基、3-戊烯基、4-戊烯基、2-己烯基、3-己烯基、4-己烯基、5-己烯基、2-甲基-2-丙烯基和4-甲基-3-戊烯基。当本发明的化合物含有亚烯基时,所述化合物可以纯E(异侧(entgegen))形式、纯Z(同侧(zusammen))形式或其任意混合物形式存在。
As used herein, the term "alkenyl" means a linear or branched monovalent hydrocarbon group containing one double bond and having 2-6 carbon atoms ("C 2-6 alkenyl"). The alkenyl groups are, for example, vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2- - Hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl. When a compound of the present invention contains an alkenylene group, the compound may exist in pure E (entgegen) form, pure Z (zusammen) form, or any mixture thereof.
如本文中所使用,术语“炔基”表示包含一个或多个三键的单价烃基,其优选具有2、3、4、5或6个碳原子,例如乙炔基或丙炔基。As used herein, the term "alkynyl" refers to a monovalent hydrocarbon group containing one or more triple bonds, preferably having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.
如本文中所使用,术语“环烷基”指饱和的单环或多环(诸如双环)烃环(例如单环,诸如环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基,或双环,包括螺环、稠合或桥连系统(诸如双环[1.1.1]戊基、双环[2.2.1]庚基、双环[3.2.1]辛基或双环[5.2.0]壬基、十氢化萘基等)),其任选地被1或多个(诸如1至3个)适合的取代基取代。所述环烷基具有3至15个碳原子。例如,术语“C
3-6环烷基”指3至6个成环碳原子的饱和的单环或多环(诸如双环)烃环(例如环丙基、环丁基、环戊基或环己基),其任选地被1或多个(诸如1至3个)适合的取代基取代,例如甲基取代的环丙基。
As used herein, the term "cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (eg, monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) , cyclooctyl, cyclononyl, or bicyclic, including spiro, fused, or bridged systems (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.)), which are optionally substituted with 1 or more (such as 1 to 3) suitable substituents. The cycloalkyl group has 3 to 15 carbon atoms. For example, the term "C 3-6 cycloalkyl" refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (eg, cyclopropyl, cyclobutyl, cyclopentyl or cyclo) of 3 to 6 ring carbon atoms hexyl), which is optionally substituted with 1 or more (such as 1 to 3) suitable substituents, eg methyl substituted cyclopropyl.
如本文中所使用,术语“亚环烃基”、“环烃基”和“烃环”是指具有例如3-10个(适合地具有3-8个,更适合地具有3-6个)环碳原子的饱和(即,“亚环烷基”和“环烷基”)或不饱和的(即在环内具有一个或多个双键和/或三键)单环或多环(包括螺环、稠合或桥连系统)烃环,其包括但不限于(亚)环丙基(环)、(亚)环丁基(环)、(亚)环戊基(环)、(亚)环己基(环)、(亚)环庚基(环)、(亚)环辛基(环)、(亚)环壬基(环)、(亚)环己烯基(环)等。As used herein, the terms "cyclohydrocarbylene", "cyclohydrocarbyl" and "hydrocarbon ring" refer to rings having, for example, 3-10 (suitably 3-8, more suitably 3-6) ring carbons Atoms saturated (ie, "cycloalkylene" and "cycloalkyl") or unsaturated (ie having one or more double and/or triple bonds in the ring) monocyclic or polycyclic (including spirocycles) , fused or bridged systems) hydrocarbon rings including, but not limited to ()cyclopropylidene (ring), ()cyclobutylidene (ring), ()cyclopentylene (ring), ()cyclopentylene Hexyl (ring), ()cycloheptylidene (ring), ()cyclooctyl (ring), ()cyclononyl (ring), ()cyclohexenyl (ring) and the like.
如本文中所使用,术语“杂环基”、“亚杂环基”和“杂环”是指具有例如3-10个(适合地具有3-8个, 更适合地具有3-6个)环原子、其中至少一个环原子是选自N、O和S的杂原子且其余环原子是C的饱和(即,杂环烷基)或部分不饱和的(即在环内具有一个或多个双键和/或三键)环状基团。例如,“3-10元(亚)杂环(基)”是具有2-9个(如2、3、4、5、6、7、8或9个)环碳原子和独立地选自N、O和S的一个或多个(例如1个、2个、3个或4个)杂原子的饱和或部分不饱和(亚)杂环(基)。亚杂环基和杂环(基)的实例包括但不限于:(亚)环氧乙烷基、(亚)氮丙啶基、(亚)氮杂环丁基(azetidinyl)、(亚)氧杂环丁基(oxetanyl)、(亚)四氢呋喃基、(亚)二氧杂环戊烯基(dioxolinyl)、(亚)吡咯烷基、(亚)吡咯烷酮基、(亚)咪唑烷基、(亚)吡唑烷基、(亚)吡咯啉基、(亚)四氢吡喃基、(亚)哌啶基、(亚)吗啉基、(亚)二噻烷基(dithianyl)、(亚)硫吗啉基、(亚)哌嗪基或(亚)三噻烷基(trithianyl)。所述基团也涵盖双环系统,包括螺环、稠合或桥连系统(诸如8-氮杂螺[4.5]癸烷、3,9-二氮杂螺[5.5]十一烷、2-氮杂双环[2.2.2]辛烷等)。亚杂环基和杂环(基)可任选地被一个或多个(例如1个、2个、3个或4个)适合的取代基取代。As used herein, the terms "heterocyclyl", "heterocyclylene" and "heterocycle" mean having, for example, 3-10 (suitably 3-8, more suitably 3-6) Ring atoms in which at least one ring atom is a heteroatom selected from N, O, and S and the remaining ring atoms are saturated (ie, heterocycloalkyl) or partially unsaturated (ie, have one or more within the ring double and/or triple bonds) cyclic groups. For example, a "3-10 membered (sub)heterocycle (radical)" is one having 2-9 (eg, 2, 3, 4, 5, 6, 7, 8, or 9) ring carbon atoms and is independently selected from N A saturated or partially unsaturated (sub)heterocycle (radical) of one or more (eg 1, 2, 3 or 4) heteroatoms of , O and S. Examples of heterocyclylenes and heterocycle(radicals) include, but are not limited to: ()oxiranyl, ()aziridinyl, (azetidinyl), ()oxygenide Heterocyclobutyl (oxetanyl), ()tetrahydrofuranyl, ()dioxolinyl (dioxolinyl), ()pyrrolidine, ()pyrrolidone, ()imidazolidinylene, () ) Pyrazolidine, () Pyrrolidene, () Tetrahydropyranyl, () Piperidinyl, () Morpholinyl, () Dithianyl (dithianyl), () Thiomorpholinyl, ()piperazinylidene or (trithianylidene)trithianyl. The groups also encompass bicyclic ring systems, including spiro, fused or bridged systems (such as 8-azaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2-nitrogen Heterobicyclo[2.2.2]octane, etc.). Heterocyclylene and heterocycle(radicals) may be optionally substituted with one or more (eg, 1, 2, 3, or 4) suitable substituents.
如本文中所使用,术语“(亚)芳基”和“芳环”指具有共轭π电子系统的全碳单环或稠合环多环芳族基团。例如,如本文中所使用,术语“C
6-10(亚)芳基”和“C
6-10芳环”意指含有6至10个碳原子的芳族基团,诸如(亚)苯基(苯环)或(亚)萘基(萘环)。(亚)芳基和芳环任选地被1或多个(诸如1至3个)适合的取代基(例如卤素、-OH、-CN、-NO
2、C
1-6烷基等)取代。(亚)芳基和芳环任选地与另一个环(例如C
3-10烃环、3-10元杂环或5-14元杂芳环)稠合,稠合的基团例如为
As used herein, the terms "()arylene" and "aromatic ring" refer to an all-carbon monocyclic or fused ring polycyclic aromatic group having a conjugated pi electron system. For example, as used herein, the terms "C 6-10 ()arylene" and "C 6-10 aromatic ring" mean an aromatic group containing 6 to 10 carbon atoms, such as ()phenylene (benzene ring) or ()naphthylene (naphthalene ring). The ()arylene and aromatic rings are optionally substituted with 1 or more (such as 1 to 3) suitable substituents (eg, halogen, -OH, -CN, -NO2 , C1-6 alkyl, etc.) . The ()arylene and aromatic rings are optionally fused with another ring (eg, a C 3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, or a 5-14 membered heteroaromatic ring), for example, the fused group is
如本文中所使用,术语“(亚)杂芳基”和“杂芳环”指单环、双环或三环芳族环系,其具有5、6、8、9、10、11、12、13或14个环原子,特别是1或2或3或4或5或6或9或10个碳原子,且其包含至少一个可以相同或不同的杂原子(所述杂原子是例如氧、氮或硫),并且,另外在每一种情况下可为苯并稠合的。特别地,“(亚)杂芳基”或“杂芳环”选自(亚)噻吩基、(亚)呋喃基、(亚)吡咯基、(亚)噁唑基、(亚)噻唑基、(亚)咪唑基、(亚)吡唑基、(亚)异噁唑基、(亚)异噻唑基、(亚)噁二唑基、(亚)三唑基、(亚)噻二唑基等,以及它们的苯并衍生物;或(亚)吡啶基、(亚)哒嗪基、(亚)嘧啶基、(亚)吡嗪基、(亚)三嗪基等,以及它们的苯并衍生物。所述“(亚)杂芳基”和“杂芳环”还可任选地与另一个环(例如C
3-10烃环、3-10元杂环、C
6-10芳环或5-14元杂芳环)稠合,稠合的基团例如为
As used herein, the terms "()heteroarylidene" and "heteroaromatic ring" refer to monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms, and which contain at least one heteroatom (such as oxygen, nitrogen, etc.) which may be the same or different or sulfur) and, in addition, can be benzo-fused in each case. In particular, "()heteroarylene" or "heteroaromatic ring" is selected from ()thienylene, ()furanyl, ()pyrrolylene, ()oxazolylylene, ()thiazolylylene, ()imidazolylidene, ()pyrazolylidene, ()isoxazolylidene, ()isothiazolylidene, ()oxadiazolylidene, ()triazolylidene, ()thiadiazolylidene etc., and their benzo derivatives; or ()pyridylene, ()pyridazinylene, ()pyrimidinylene, ()pyrazinylene, ()triazinylene, etc., and their benzos derivative. The "()heteroarylene" and "heteroaromatic ring" may also optionally be combined with another ring (eg, a C3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, a C6-10 aromatic ring, or a 5- 14-membered heteroaromatic ring) condensed, the condensed group is for example
如本文中所使用,术语“芳烷基”优选表示芳基或杂芳基取代的烷基,其中所述芳基、杂芳基和烷基如本文中所定义。通常,所述芳基可具有6-14个碳原子,所述杂芳基可具有5-14个环原子,并且所述烷基可具有1-6个碳原子。示例性芳烷基包括但不限于苄基、苯基乙基、苯基丙基、苯基丁基。As used herein, the term "aralkyl" preferably refers to an aryl or heteroaryl substituted alkyl group, wherein said aryl, heteroaryl and alkyl groups are as defined herein. Typically, the aryl group can have 6-14 carbon atoms, the heteroaryl group can have 5-14 ring atoms, and the alkyl group can have 1-6 carbon atoms. Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.
如本文中所使用,术语“卤代”或“卤素”基团定义为包括F、Cl、Br或I。As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br or I.
如本文中所使用,术语“含氮杂环”指饱和或不饱和的单环或双环基团,其在环中具有2、3、4、5、6、7、8、9、10、11、12或13个碳原子和至少一个氮原子,其还可任选地包含一个或多个(例如一个、两个、三个或四个)选自N、O、C=O、S、S=O和S(=O)
2的环成员,其通过所述含氮杂环中的氮原子以及任一其余环原子与分子的其余部分连接,所述含氮杂环任选地为苯并稠合的,并且优选通过所述含氮杂环中的氮原子以及所稠合的苯环中的任一碳原子与分子的其余部分连接。
As used herein, the term "nitrogen-containing heterocycle" refers to a saturated or unsaturated monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 in the ring , 12 or 13 carbon atoms and at least one nitrogen atom, which may also optionally contain one or more (eg one, two, three or four) selected from N, O, C=O, S, S A ring member of =O and S(=O) 2 , which is attached to the rest of the molecule through a nitrogen atom in the nitrogen-containing heterocycle, optionally benzo, and any remaining ring atoms fused, and preferably attached to the remainder of the molecule through a nitrogen atom in the nitrogen-containing heterocycle and any carbon atom in the fused benzene ring.
术语“取代”指所指定的原子上的一个或多个(例如一个、两个、三个或四个)氢被从所指出的基团的选择代替,条件是未超过所指定的原子在当前情况下的正常原子价并且所述取代形成稳定的化合物。取代基和/或变量的组合仅仅当这种组合形成稳定的化合物时才是允许的。The term "substituted" means that one or more (eg, one, two, three, or four) hydrogens on the designated atom are replaced by a selection from the designated group, provided that no more than the designated atom is present in the normal valences in the case and the substitutions form stable compounds. Combinations of substituents and/or variables are permissible only if such combinations form stable compounds.
如果取代基被描述为“任选地被取代”,则取代基可(1)未被取代或(2)被取代。如果取代基的碳被描述为任选地被取代基列表中的一个或多个取代,则碳上的一个或多个氢(至存在的任何氢的程度)可单独和/或一起被独立地选择的任选的取代基替代。如果取代基的氮被描述为任选地被取代基列表中的一个或多个取代,则氮上的一个或多个氢(至存在的任何氢的程度)可各自被独立地选择的任选的取代基替代。If a substituent is described as "optionally substituted," the substituent can be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the list of substituents, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be independently and/or together independently Selected optional substituents are substituted. If a nitrogen of a substituent is described as being optionally substituted with one or more of the list of substituents, then one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be independently selected optional substitution of substituents.
如果取代基被描述为“独立地选自”一组,则各取代基独立于另一者被选择。因此,各取代基可与另一(其他)取代基相同或不同。If substituents are described as being "independently selected from" a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
如本文中所使用,术语“一个或多个”意指在合理条件下的1个或超过1个,例如2个、3个、4个、5个或10个。As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, under reasonable conditions.
除非指明,否则如本文中所使用,取代基的连接点可来自取代基的任意适宜位置。Unless indicated, as used herein, the point of attachment of a substituent can be from any suitable position on the substituent.
当取代基的键显示为穿过环中连接两个原子的键时,则这样的取代基可键连至该可取代的环中的任一成环原子。When the bond of a substituent is shown as a bond connecting two atoms in a ring, such substituent may be bonded to any ring-forming atom in the substitutable ring.
本发明还包括所有药学上可接受的同位素标记的化合物,其与本发明的化合物相同,除了一个 或多个原子被具有相同原子序数但原子质量或质量数不同于在自然界中占优势的原子质量或质量数的原子替代。适合包含入本发明的化合物中的同位素的实例包括(但不限于)氢的同位素(例如氘(
2H)、氚(
3H));碳的同位素(例如
11C、
13C及
14C);氯的同位素(例如
36Cl);氟的同位素(例如
18F);碘的同位素(例如
123I及
125I);氮的同位素(例如
13N及
15N);氧的同位素(例如
15O、
17O及
18O);磷的同位素(例如
32P);及硫的同位素(例如
35S)。某些同位素标记的本发明的化合物(例如掺入放射性同位素的那些)可用于药物和/或底物组织分布研究(例如分析)中。放射性同位素氚(即
3H)及碳-14(即
14C)因易于掺入且容易检测而特别可用于该目的。用正电子发射同位素(例如
11C、
18F、
15O及
13N)进行取代可在正电子发射断层显像术(PET)研究中用于检验底物受体占据情况。被同位素标记的本发明的化合物可通过与描述于随附路线和/或实施例及制备中的那些类似的方法通过使用适当的被同位素标记的试剂代替之前采用的非标记的试剂来制备。本发明的药学上可接受的溶剂合物包括其中结晶溶剂可被同位素取代的那些,例如,D
2O、丙酮-d
6或DMSO-d
6。
The present invention also includes all pharmaceutically acceptable isotopically-labeled compounds that are identical to the compounds of the present invention, except that one or more atoms have the same atomic number but an atomic mass or mass number different from the atomic mass that predominates in nature or atomic substitution of mass numbers. Examples of isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen (eg, deuterium (2H), tritium ( 3H )); isotopes of carbon (eg, 11C , 13C , and14C ) ; isotopes of chlorine (eg 36 Cl); isotopes of fluorine (eg 18 F); isotopes of iodine (eg 123 I and 125 I); isotopes of nitrogen (eg 13 N and 15 N); isotopes of oxygen (eg 15 O) , 17 O and 18 O); isotopes of phosphorus (eg 32 P); and isotopes of sulfur (eg 35 S). Certain isotopically-labeled compounds of the invention (eg, those incorporating radioisotopes) are useful in drug and/or substrate tissue distribution studies (eg, assays). The radioisotopes tritium (ie 3 H) and carbon-14 (ie 14 C) are particularly useful for this purpose due to their ease of incorporation and ease of detection. Substitution with positron emitting isotopes such as11C , 18F , 15O , and13N can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the invention can be prepared by methods analogous to those described in the accompanying Schemes and/or Examples and Preparations by using an appropriate isotopically labeled reagent in place of the previously employed non-labeled reagent. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent may be isotopically substituted, eg, D2O , acetone-d6, or DMSO - d6.
术语“立体异构体”表示由于至少一个不对称中心形成的异构体。在具有一个或多个(例如一个、两个、三个或四个)不对称中心的化合物中,其可产生外消旋混合物、单一对映异构体、非对映异构体混合物和单独的非对映异构体。特定个别分子也可以几何异构体(顺式/反式)存在。类似地,本发明的化合物可以两种或更多种处于快速平衡的结构不同的形式的混合物(通常称作互变异构体)存在。互变异构体的代表性实例包括酮-烯醇互变异构体、苯酚-酮互变异构体、亚硝基-肟互变异构体、亚胺-烯胺互变异构体等。要理解,本申请的范围涵盖所有这样的以任意比例(例如60%、65%、70%、75%、80%、85%、90%、95%、96%、97%、98%、99%)的异构体或其混合物。The term "stereoisomer" refers to isomers formed due to at least one asymmetric center. In compounds having one or more (eg, one, two, three or four) asymmetric centers, it may give rise to racemic mixtures, single enantiomers, diastereomeric mixtures and individual of diastereomers. Certain individual molecules can also exist as geometric isomers (cis/trans). Similarly, the compounds of the present invention may exist as mixtures of two or more structurally distinct forms in rapid equilibrium (often referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers Wait. It is to be understood that the scope of this application covers all such in any ratio (eg 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% %) of isomers or mixtures thereof.
本文中可使用实线
实楔形
或虚楔形
描绘本发明的化合物的化学键。使用实线以描绘键连至不对称碳原子的键欲表明,包括该碳原子处的所有可能的立体异构体(例如,特定的对映异构体、外消旋混合物等)。使用实或虚楔形以描绘键连至不对称碳原子的键欲表明,存在所示的立体异构体。当存在于外消旋混合物中时,使用实及虚楔形以定义相对立体化学,而非绝对立体化学。除非另外指明,否则本发明的化合物意欲可以立体异构体(其包括顺式及反式异构体、光学异构体(例如R及S对映异构体)、非对映异构体、几何异构体、旋转异构体、构象异构体、阻转异构体及其混合物)的形式存在。本发明的化合物可表现一种以上类型的异构现象,且由其混合物(例如外消旋混合物及非对映异构体对)组成。
Solid lines may be used in this article solid wedge or virtual wedge The chemical bonds of the compounds of the present invention are depicted. The use of a solid line to depict a bond to an asymmetric carbon atom is intended to indicate that all possible stereoisomers at that carbon atom are included (eg, a specific enantiomer, racemic mixture, etc.). The use of real or dashed wedges to delineate bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomer exists. When present in a racemic mixture, real and imaginary wedges are used to define relative, rather than absolute, stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to be available as stereoisomers (which include cis and trans isomers, optical isomers (eg, R and S enantiomers), diastereomers, Geometric isomers, rotational isomers, conformational isomers, atropisomers and mixtures thereof). The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (eg, racemic mixtures and pairs of diastereomers).
本发明涵盖本发明的化合物的所有可能的结晶形式或多晶型物,其可为单一多晶型物或多于一种多晶型物的任意比例的混合物。The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of more than one polymorph in any ratio.
还应当理解,本发明的某些化合物可以游离形式存在用于治疗,或适当时,以其药学上可接受的衍生物形式存在。在本发明中,药学上可接受的衍生物包括但不限于,药学上可接受的盐、酯、溶剂合物、N-氧化物、代谢物或前药,在将它们向需要其的患者给药后,能够直接或间接提供本发明的化合物或其代谢物或残余物。因此,当在本文中提及“本发明的化合物”时,也意在涵盖化合物的上述各种衍生物形式。It will also be appreciated that certain compounds of the present invention may exist in free form for use in therapy, or, where appropriate, in the form of their pharmaceutically acceptable derivatives. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites or prodrugs which are administered to patients in need thereof After administration, the compounds of the invention or their metabolites or residues can be provided directly or indirectly. Accordingly, references herein to "compounds of the present invention" are also intended to encompass the various derivative forms of the compounds described above.
本发明的化合物的药学上可接受的盐包括其酸加成盐及碱加成盐。Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
适合的酸加成盐由形成药学可接受盐的酸来形成。实例包括乙酸盐、己二酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、碳酸氢盐/碳酸盐、硫酸氢盐/硫酸盐、硼酸盐、樟脑磺酸盐、柠檬酸盐、环己氨磺酸盐、乙二磺酸盐、乙磺酸盐、甲酸盐、延胡索酸盐、葡庚糖酸盐、葡糖酸盐、葡糖醛酸盐、六氟磷酸盐、海苯酸盐、盐酸盐/氯化物、氢溴酸盐/溴化物、氢碘酸盐/碘化物、羟乙基磺酸盐、乳酸盐、苹果酸盐、顺丁烯二酸盐、丙二酸盐、甲磺酸盐、甲基硫酸盐、萘甲酸盐(naphthylate)、2-萘磺酸盐、烟酸盐、硝酸盐、乳清酸盐、草酸盐、棕榈酸盐、双羟萘酸盐、磷酸盐/磷酸氢盐/磷酸二氢盐、焦谷氨酸盐、糖二酸盐、硬脂酸盐、丁二酸盐、单宁酸盐、酒石酸盐、甲苯磺酸盐、三氟乙酸盐及昔萘酸盐(xinofoate)。Suitable acid addition salts are formed from acids which form pharmaceutically acceptable salts. Examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camphorsulphonate , citrate, cyclamate, ethanedisulfonate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate Salt, Hyphenate, Hydrochloride/Chloride, Hydrobromide/Bromide, Hydroiodide/Iodide, Isethionate, Lactate, Malate, Maleic Acid salt, malonate, mesylate, methyl sulfate, naphthylate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitic acid Salt, Pamoate, Phosphate/Hydrogen Phosphate/Dihydrogen Phosphate, Pyroglutamate, Saccharate, Stearate, Succinate, Tannin, Tartrate, Toluene Sulfonate, trifluoroacetate and xinofoate.
适合的碱加成盐由形成药学可接受盐的碱来形成。实例包括铝盐、精氨酸盐、苄星青霉素盐、钙盐、胆碱盐、二乙胺盐、二乙醇胺盐、甘氨酸盐、赖氨酸盐、镁盐、葡甲胺盐、乙醇胺盐、钾盐、钠盐、氨丁三醇盐及锌盐。Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts. Examples include aluminum salts, arginine salts, benzathine penicillin salts, calcium salts, choline salts, diethylamine salts, diethanolamine salts, glycinate salts, lysine salts, magnesium salts, meglumine salts, ethanolamine salts, Potassium, sodium, tromethamine and zinc salts.
适合的盐的综述参见Stahl及Wermuth的“Handbook of Pharmaceutical Salts:Properties,Selection,and Use”(Wiley-VCH,2002)。用于制备本发明的化合物的药学上可接受的盐的方法为本领域技术人员已知的。For a review of suitable salts see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds of the present invention are known to those skilled in the art.
如本文中所使用,术语“酯”意指衍生自本申请中各个通式化合物的酯,其包括生理上可水解的酯(可在生理条件下水解以释放游离酸或醇形式的本发明的化合物)。本发明的化合物本身也可以是酯。As used herein, the term "ester" means an ester derived from each of the compounds of the general formula in this application, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release free acid or alcohol forms of the present invention) compound). The compounds of the present invention may themselves also be esters.
本发明的化合物可以溶剂合物(优选水合物)的形式存在,其中本发明的化合物包含作为所述化合物晶格的结构要素的极性溶剂,特别是例如水、甲醇或乙醇。极性溶剂特别是水的量可以化学计量比或非化学计量比存在。The compounds of the present invention may exist in the form of solvates, preferably hydrates, wherein the compounds of the present invention comprise a polar solvent as a structural element of the crystal lattice of the compound, in particular for example water, methanol or ethanol. The amount of polar solvent, especially water, may be present in stoichiometric or non-stoichiometric ratios.
本领域技术人员会理解,由于氮需要可用的孤对电子来氧化成氧化物,因此并非所有的含氮杂环都能够形成N-氧化物;本领域技术人员会识别能够形成N-氧化物的含氮杂环。本领域技术人员还会认识到叔胺能够形成N-氧化物。用于制备杂环和叔胺的N-氧化物的合成方法是本领域技术人员熟知的,包括用过氧酸如过氧乙酸和间氯过氧苯甲酸(MCPBA)、过氧化氢、烷基过氧化氢如叔丁基过氧化氢、过硼酸钠和双环氧乙烷(dioxirane)如二甲基双环氧乙烷来氧化杂环和叔胺。这些用于制备N-氧化物的方法已在文献中得到广泛描述和综述,参见例如:T.L.Gilchrist,Comprehensive Organic Synthesis,vol.7,pp 748-750;A.R.Katritzky和A.J.Boulton,Eds.,Academic Press;以及G.W.H.Cheeseman和E.S.G.Werstiuk,Advances in Heterocyclic Chemistry,vol.22,pp 390-392,A.R.Katritzky和A.J.Boulton,Eds.,Academic Press。Those skilled in the art will appreciate that not all nitrogen-containing heterocycles are capable of forming N-oxides since nitrogen requires available lone pairs of electrons to oxidize to oxides; Nitrogen-containing heterocycles. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are well known to those skilled in the art and include the use of peroxyacids such as peracetic acid and m-chloroperoxybenzoic acid (MCPBA), hydrogen peroxide, alkyl Hydrogen peroxides such as t-butyl hydroperoxide, sodium perborate and dioxiranes such as dimethyldioxirane are used to oxidize heterocycles and tertiary amines. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see e.g.: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press ; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
在本发明的范围内还包括本发明的化合物的代谢物,即在给药本发明的化合物时体内形成的物质。这样的产物可由例如被给药的化合物的氧化、还原、水解、酰胺化、脱酰胺化、酯化、酶解等产生。因此,本发明包括本发明的化合物的代谢物,包括通过使本发明的化合物与哺乳动物接触足以产生其代谢产物的时间的方法制得的化合物。Also included within the scope of the present invention are metabolites of the compounds of the present invention, ie substances formed in the body upon administration of the compounds of the present invention. Such products may result from, for example, oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, and the like, of the administered compound. Accordingly, the present invention includes metabolites of the compounds of the present invention, including compounds prepared by methods of contacting a compound of the present invention with a mammal for a time sufficient to produce the metabolites thereof.
本发明在其范围内进一步包括本发明的化合物的前药,其为自身可具有较小药理学活性或无药理学活性的本发明的化合物的某些衍生物当被给药至身体中或其上时可通过例如水解裂解转化成具有期望活性的本发明的化合物。通常这样的前药会是所述化合物的官能团衍生物,其易于在体内转化成期望的治疗活性化合物。关于前药的使用的其他信息可参见“Pro-drugs as Novel Delivery Systems”,第14卷,ACS Symposium Series(T.Higuchi及V.Stella)。本发明的前药可例如通过用本领域技术人员已知作为“前-部分(pro-moiety)(例如“Design of Prodrugs”,H.Bundgaard(Elsevier,1985)中所述)”的某些部分替代本发明的化合物中存在的适当官能团来制备。The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity when administered into or onto the body can be converted into compounds of the invention having the desired activity, for example, by hydrolytic cleavage. Typically such prodrugs will be functional derivatives of the compound that are readily converted in vivo to the desired therapeutically active compound. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella). The prodrugs of the present invention can be obtained, for example, by using certain moieties known to those skilled in the art as "pro-moiety (eg as described in "Design of Prodrugs", H. Bundgaard (Elsevier, 1985))" Prepared by substituting appropriate functional groups present in the compounds of the present invention.
本发明还涵盖含有保护基的本发明的化合物。在制备本发明的化合物的任何过程中,保护在任何有关分子上的敏感基团或反应基团可能是必需的和/或期望的,由此形成本发明的化合物的化学保护的形式。这可以通过常规的保护基实现,例如,在T.W.Greene & P.G.M.Wuts,Protective Groups in Organic Synthesis,John Wiley & Sons,1991中所述的那些保护基,这些参考文献通过援引加入本文。使用本领域已知的方法,在适当的后续阶段可以移除保护基。The present invention also encompasses compounds of the present invention that contain protecting groups. In any process for preparing the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any relevant molecule, thereby forming chemically protected forms of the compounds of the present invention. This can be accomplished with conventional protecting groups, such as those described in T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
术语“约”是指在所述数值的±10%范围内,优选±5%范围内,更优选±2%范围内。The term "about" means within ±10% of the stated value, preferably within ±5%, more preferably within ±2%.
化合物compound
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(I)的结构:In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (I):
其中:in:
X
1、X
2、X
3和X
4各自独立地选自C=O、CH
2、CHR、C(R)
2和N-L-R
2,优选地,X
1、X
2、X
3和X
4中至少一个为N-L-R
2;
X 1 , X 2 , X 3 and X 4 are each independently selected from C=O, CH 2 , CHR, C(R) 2 and NLR 2 , preferably, at least among X 1 , X 2 , X 3 and X 4 One is NLR 2 ;
L选自直接键、C
1-6亚烷基、C(=O)、O、S(=O)、S(=O)
2和NR
4;
L is selected from direct bond, C1-6 alkylene, C(=O), O, S(=O), S(=O) 2 and NR4 ;
环B选自C
3-10烃环、3-10元杂环、C
6-10芳环和5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O);
Ring B is selected from C 3-10 hydrocarbon rings, 3-10-membered heterocycles, C 6-10 -membered aromatic rings and 5-14-membered heteroaromatic rings, wherein at most 2 ring members of the hydrocarbon rings and heterocycles are C(= O);
R和R
1在每次出现时各自独立地选自卤素、-NH
2、-CN、-NO
2、-OH、-O-C
1-6烷基、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基和C
6-12芳烷基,所述环烃基和杂环基中至多2个环成员为C(=O),当m大于1和/或n大于1时,两个R
1和/或两个R连同其所连接的原子任选地共同构成C
3-10烃环、3-10元杂环、C
6-10芳环或5-14元杂芳环,所述烃环 和杂环中至多2个环成员为C(=O);
R and R 1 are each independently selected at each occurrence from halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, C 1-6 alkyl, halogenated C 1- 6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl, saturated or partially unsaturated C 3-10 Cyclic hydrocarbon groups, saturated or partially unsaturated 3-10 membered heterocyclic groups, C 6-10 aryl groups, 5-14 membered heteroaryl groups and C 6-12 aralkyl groups, among the cyclic hydrocarbon groups and heterocyclic groups at most 2 ring members are C(=O), when m is greater than 1 and/or n is greater than 1, two R 1 and/or two R together with the atoms to which they are attached optionally together form a C 3-10 hydrocarbon ring , 3-10-membered heterocyclic ring, C 6-10 -membered aromatic ring or 5-14-membered heteroaromatic ring, wherein at most 2 ring members in the hydrocarbon ring and the heterocyclic ring are C(=O);
R
2选自H、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6、-C
1-6亚烷基-O(P=O)(OH)
2和-O-C
1-6亚烷基-NR
5R
6;
R 2 is selected from H, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl , C 2-6 alkynyl, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl, -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O) R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 sub Alkyl-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;
R
3和R
4各自独立地选自H、卤素、-NH
2、-CN、-NO
2、-OH、-O-C
1-6烷基、-O-(3-10元杂环基)、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、C
2-6烯基、C
2-6炔基、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6、-C
1-6亚烷基-O(P=O)(OH)
2和-O-C
1-6亚烷基-NR
5R
6;
R 3 and R 4 are each independently selected from H, halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, -O-(3-10 membered heterocyclyl), C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl , saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl group , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O ) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 - C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;
上述基团在每次出现时各自任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH
2、-CN、-NO
2、C
1-6烷基、C
2-6烯基、C
2-6炔基、C
3-6环烃基、3-10元杂环基、C
6-10芳基、5-14元杂芳基、C
6-12芳烷基、=N-OR
5、-C(=NH)NH
2、-C(=O)R
5、-OC(=O)R
5、-C(=O)OR
5、-OR
5、-SR
5、-S(=O)R
5、-S(=O)
2R
5、-S(=O)
2NR
5R
6、-NR
5R
6、-C(=O)NR
5R
6、-NR
5-C(=O)R
6、-NR
5-C(=O)OR
6、-NR
5-S(=O)
2-R
6、-NR
5-C(=O)-NR
5R
6、-C
1-6亚烷基-NR
5R
6和-O-C
1-6亚烷基-NR
5R
6,所述烷基、环烃基、杂环基、芳基、杂芳基和芳烷基进一步任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH
2、-CN、-NO
2、C
1-6烷基、C
3-6环烃基、3-10元杂环基、C
6-10芳基、5-14元杂芳基和C
6-12芳烷基;
The above groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, -NH2 , -CN, -NO2 , C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered heteroaryl, C 6- 12 Aralkyl, =N-OR 5 , -C(=NH)NH 2 , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O) -NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 and -OC 1-6 alkylene-NR 5 R 6 , the alkyl, cyclohydrocarbyl, heterocyclyl, aryl, heterocyclyl Aryl and aralkyl are further optionally substituted with one or more substituents independently selected from halogen, -OH, oxo, -NH2 , -CN, -NO2 , Ci_6alkyl , C 3-6 cyclic hydrocarbon group, 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group and C 6-12 aralkyl group;
R
5和R
6在每次出现时各自独立地选自H、C
1-6烷基、C
3-10环烃基、3-10元杂环基、C
6-10芳基、5-14元杂芳基和C
6-12芳烷基;并且
R 5 and R 6 at each occurrence are each independently selected from H, C 1-6 alkyl, C 3-10 cyclohydrocarbyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered Heteroaryl and C 6-12 aralkyl; and
m为选自0、1、2、3和4的整数。m is an integer selected from 0, 1, 2, 3 and 4.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(II)的结构:In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (II):
n为选自0、1、2或3的整数。n is an integer selected from 0, 1, 2 or 3.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中L为直接键、-CH
2-或C(=O)。
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , where L is a direct bond, -CH 2 - or C(=O).
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中,R
2为饱和或部分不饱和的C
3-10环烃基或饱和或部分不饱和的3-10元杂环基,其中所述环烃基和杂环基任选地被一个或多个选自-C(=O)R
5和-C(=O)NR
5R
6的取代基取代;
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein R 2 is a saturated or partially unsaturated C 3-10 cyclic hydrocarbon group or a saturated or partially unsaturated 3-10-membered heterocyclic group, wherein the cyclic hydrocarbon group and the heterocyclic group are optionally composed of one or more Substituents selected from -C(=O)R 5 and -C(=O)NR 5 R 6 are substituted;
优选地,R
2为环丁烷基、环己烷基、哌啶基或四氢吡喃基,其任选地被一个或多个选自-C(=O)CH
3和-C(=O)N(CH
3)
2的取代基取代;
Preferably, R 2 is cyclobutanyl, cyclohexyl, piperidinyl or tetrahydropyranyl, optionally by one or more selected from -C(=O) CH3 and -C(= O) Substituent substitution of N(CH 3 ) 2 ;
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中环B为双环[1.1.1]戊烷环、2-氧杂双环[2.1.1]己烷环、苯环或噻吩环,最优选为苯环或噻吩环。In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein ring B is a bicyclo[1.1.1]pentane ring, a 2-oxabicyclo[2.1.1]hexane ring, a benzene ring or a thiophene ring, most preferably a benzene ring or a thiophene ring.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R
1在每次出现时各自独立地选自卤素、-NH
2、C
1-6烷基、卤代C
1-6烷基、C
1-6亚烷基-OH、卤代C
1-6亚烷基-OH、饱和或部分不饱和的C
3-10环烃基、饱和或部分不饱和的3-10元杂环基、C
6-10芳基和5-14元杂芳基,所述亚烷基、烷基、环烃基、杂环基、芳基和杂芳基任选地被一个或多个独立地选自卤素、-OH、C
3-6环烃基、3-10元杂环基、C
6-10芳基和5-14元杂芳基的取代基取代;
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein each occurrence of R 1 is independently selected from halogen, -NH 2 , C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1 -6 alkylene-OH, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10 membered heterocyclyl, C 6-10 aryl and 5-14 membered heteroaryl, The alkylene, alkyl, cyclohydrocarbyl, heterocyclyl, aryl, and heteroaryl groups are optionally one or more independently selected from halogen, -OH, C 3-6 cyclohydrocarbyl, 3-10 membered Substituent substitution of heterocyclyl, C 6-10 aryl and 5-14 membered heteroaryl;
当m大于1时,两个R
1连同其所连接的原子任选地共同构成C
3-10烃环、3-10元杂环、C
6-10芳环或5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O),并且所述烃环、杂环、芳环和杂芳环任选地被一个或多个卤素取代;
When m is greater than 1, the two R 1 together with the atoms to which they are attached optionally together form a C 3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, a C 6-10 aromatic ring or a 5-14 membered heteroaromatic ring, Up to 2 ring members of the hydrocarbon and heterocycles are C(=O), and the hydrocarbon, heterocycle, aromatic and heteroaromatic rings are optionally substituted with one or more halogens;
优选地,R
1在每次出现时各自独立地选自CF
3、NH
2、
并且m为1或2。
Preferably, each occurrence of R 1 is independently selected from CF 3 , NH 2 , And m is 1 or 2.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中
选自
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof ,in selected from
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R
3选自H和C
1-6烷基;优选地,R
3为甲基。
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein R 3 is selected from H and C 1-6 alkyl; preferably, R 3 is methyl.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R
4选自H和C
1-6烷基;优选地,R
4为H。
In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein R 4 is selected from H and C 1-6 alkyl; preferably, R 4 is H.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(III)的结构:In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound has the structure of formula (III):
本发明涵盖对各个实施方案进行任意组合所得的化合物。The present invention encompasses compounds resulting from any combination of the various embodiments.
在一些实施方案中,本发明提供化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物选自:In some embodiments, the present invention provides compounds, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof , wherein the compound is selected from:
药物组合物和治疗方法Pharmaceutical compositions and methods of treatment
在一些实施方案中,本发明提供药物组合物,其包含预防或治疗有效量的本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药以及一种或多种药学上可接受的载体,所述药物组合物优选为固体制剂、半固体制剂、液体制剂或气态制剂。在一些实施方案中,所述药物组合物还可包含一种或多种其它治疗剂。In some embodiments, the present invention provides pharmaceutical compositions comprising a prophylactically or therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, The N-oxide, isotope-labeled compound, metabolite or prodrug and one or more pharmaceutically acceptable carriers, the pharmaceutical composition is preferably a solid preparation, semi-solid preparation, liquid preparation or gaseous preparation. In some embodiments, the pharmaceutical composition may further comprise one or more other therapeutic agents.
在一些实施方案中,本发明提供本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物在制备用作SOS1抑制剂的药物中的用途。In some embodiments, the present invention provides compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites thereof Or prodrug or use of the pharmaceutical composition of the present invention in the preparation of a medicament for use as an inhibitor of SOS1.
在一些实施方案中,本发明提供本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物,其用作SOS1抑制剂。In some embodiments, the present invention provides compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites thereof or a prodrug or a pharmaceutical composition of the present invention, which acts as a SOS1 inhibitor.
在一些实施方案中,本发明提供预防或治疗SOS1相关疾病的方法,所述方法包括向需要其的个体给药有效量的本发明的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者本发明的药物组合物。In some embodiments, the present invention provides a method of preventing or treating an SOS1-related disease, the method comprising administering to an individual in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer thereof body, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug or pharmaceutical composition of the present invention.
在一些实施方案中,所述SOS1相关疾病包括癌症(例如胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤)、RAS病(例如1型神经纤维瘤病(NF1)、努南综合征(NS)、伴有多斑的努南综合征(NSML)、毛细血管畸形-动静脉畸形综合征(CM-AVM)、科斯特洛综合征(CS)、心-面-皮肤综合症(CFC)、莱格斯综合征和遗传性牙龈纤维瘤病)。In some embodiments, the SOS1-related disease includes cancer (eg, pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid Leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate carcinoma, glioblastoma, renal carcinoma, and sarcoma), RAS disorders (eg, neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Noonan syndrome with multiple spots (NSML), capillary Vascular malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facial-cutaneous syndrome (CFC), Leggers syndrome and hereditary gingival fibromatosis).
本发明中“药学上可接受的载体”是指与治疗剂一同给药的稀释剂、辅剂、赋形剂或媒介物,并且其在合理的医学判断的范围内适于接触人类和/或其它动物的组织而没有过度的毒性、刺激、过敏反应或与合理的益处/风险比相应的其它问题或并发症。"Pharmaceutically acceptable carrier" as used herein refers to a diluent, adjuvant, excipient or vehicle with which the therapeutic agent is administered and which, within the scope of sound medical judgment, is suitable for contact with humans and/or tissue from other animals without undue toxicity, irritation, allergic reactions, or other problems or complications commensurate with a reasonable benefit/risk ratio.
在本发明的药物组合物中可使用的药学上可接受的载体包括但不限于无菌液体,例如水和油,包括那些石油、动物、植物或合成来源的油,例如花生油、大豆油、矿物油、芝麻油等。当所述药物组合物通过静脉内给药时,水是示例性载体。还可以使用生理盐水和葡萄糖及甘油水溶液作为液体载体,特别是用于注射液。适合的药物赋形剂包括淀粉、葡萄糖、乳糖、蔗糖、明胶、麦芽糖、白垩、硅胶、硬脂酸钠、单硬脂酸甘油酯、滑石、氯化钠、脱脂奶粉、甘油、丙二醇、水、乙醇等。所述组合物还可以视需要包含少量的湿润剂、乳化剂或pH缓冲剂。口服制剂可以包含标准载体,如药物级的甘露醇、乳糖、淀粉、硬脂酸镁、糖精钠、纤维素、碳酸镁等。适合的药学上可接受的载体的实例如在Remington’s Pharmaceutical Sciences(1990)中所述。Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral Oil, sesame oil, etc. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. Physiological saline and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, nonfat dry milk, glycerin, propylene glycol, water, Ethanol etc. The composition may also contain minor amounts of wetting agents, emulsifying agents or pH buffering agents as desired. Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
本发明的药物组合物可以系统地作用和/或局部地作用。为此目的,它们可以适合的途径给药, 例如通过注射(如静脉内、动脉内、皮下、腹膜内、肌内注射,包括滴注)或经皮给药;或通过口服、含服、经鼻、透粘膜、局部、以眼用制剂的形式或通过吸入给药。The pharmaceutical compositions of the present invention may act systemically and/or locally. For this purpose they may be administered by a suitable route, for example by injection (eg intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including instillation) or transdermally; or by oral, buccal, transdermal Nasal, transmucosal, topical, in ophthalmic formulations or by inhalation.
对于这些给药途径,可以适合的剂型给药本发明的药物组合物。For these routes of administration, the pharmaceutical compositions of the present invention may be administered in suitable dosage forms.
所述剂型包括但不限于片剂、胶囊剂、锭剂、硬糖剂、散剂、喷雾剂、乳膏剂、软膏剂、栓剂、凝胶剂、糊剂、洗剂、软膏剂、水性混悬剂、可注射溶液剂、酏剂、糖浆剂。Such dosage forms include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions , injectable solutions, elixirs, syrups.
如本文中所使用的术语“有效量”指被给药后会在一定程度上缓解所治疗病症的一或多种症状的化合物的量。The term "effective amount" as used herein refers to the amount of a compound which, when administered, will alleviate to some extent one or more symptoms of the condition being treated.
可调整给药方案以提供最佳所需响应。例如,可给药单次推注,可随时间给药数个分剂量,或可如治疗情况的急需所表明而按比例减少或增加剂量。要注意,剂量值可随要减轻的病况的类型及严重性而变化,且可包括单次或多次剂量。要进一步理解,对于任何特定个体,具体的给药方案应根据个体需要及给药组合物或监督组合物的给药的人员的专业判断来随时间调整。Dosage regimens can be adjusted to provide the optimal desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is further understood that for any particular individual, the specific dosing regimen should be adjusted over time according to the needs of the individual and the professional judgment of the person administering or supervising the administration of the composition.
所给药的本发明的化合物的量会取决于所治疗的个体、病症或病况的严重性、给药的速率、化合物的处置及处方医师的判断。一般而言,有效剂量在每日每kg体重约0.0001至约50mg,例如约0.01至约10mg/kg/日(单次或分次给药)。对70kg的人而言,这会合计为约0.007mg/日至约3500mg/日,例如约0.7mg/日至约700mg/日。在一些情况下,不高于前述范围的下限的剂量水平可以是足够的,而在其它情况下,仍可在不引起任何有害副作用的情况下采用较大剂量,条件是首先将所述较大剂量分成数个较小剂量以在一整天中给药。The amount of the compound of the invention administered will depend on the individual being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound, and the judgment of the prescribing physician. In general, an effective dose will range from about 0.0001 to about 50 mg per kg of body weight per day, eg, from about 0.01 to about 10 mg/kg/day (single or divided administration). For a 70 kg person, this would add up to about 0.007 mg/day to about 3500 mg/day, eg, about 0.7 mg/day to about 700 mg/day. In some cases, dose levels not higher than the lower end of the foregoing ranges may be sufficient, while in other cases larger doses may be employed without causing any deleterious side effects, provided that the larger dose is first The dose is divided into several smaller doses to be administered throughout the day.
本发明的化合物在药物组合物中的含量或用量可以是约0.01mg至约1000mg,适合地是0.1-500mg,优选0.5-300mg,更优选1-150mg,特别优选1-50mg,例如1.5mg、2mg、4mg、10mg、25mg等。The content or amount of the compound of the present invention in the pharmaceutical composition may be about 0.01 mg to about 1000 mg, suitably 0.1-500 mg, preferably 0.5-300 mg, more preferably 1-150 mg, particularly preferably 1-50 mg, such as 1.5 mg, 2mg, 4mg, 10mg, 25mg, etc.
除非另外说明,否则如本文中所使用,术语“治疗(treating)”意指逆转、减轻、抑制这样的术语所应用的病症或病况或者这样的病症或病况的一或多种症状的进展,或预防这样的病症或病况或者这样的病症或病况的一或多种症状。Unless otherwise specified, the term "treating" as used herein means reversing, alleviating, inhibiting the progression of the disorder or condition to which such term applies or one or more symptoms of such disorder or condition, or Such a disorder or condition or one or more symptoms of such a disorder or condition is prevented.
如本文所使用的“个体”包括人或非人动物。示例性人个体包括患有疾病(例如本文所述的疾病)的人个体(称为患者)或正常个体。本发明中“非人动物”包括所有脊椎动物,例如非哺乳动物(例如鸟类、两栖动物、爬行动物)和哺乳动物,例如非人灵长类、家畜和/或驯化动物(例如绵羊、犬、猫、奶牛、猪等)。An "individual" as used herein includes a human or non-human animal. Exemplary human subjects include human subjects (referred to as patients) or normal subjects with a disease (eg, a disease described herein). "Non-human animals" in the present invention include all vertebrates such as non-mammals (eg birds, amphibians, reptiles) and mammals such as non-human primates, livestock and/or domesticated animals (eg sheep, dogs) , cats, cows, pigs, etc.).
在一些实施方案中,本发明的药物组合物还可以包含一种或多种另外的治疗剂或预防剂。In some embodiments, the pharmaceutical compositions of the present invention may further comprise one or more additional therapeutic or prophylactic agents.
以下结合实施例进一步描述本发明,但提供这些实施例并非意在限制本发明的范围。The present invention is further described below in conjunction with the examples, but these examples are not intended to limit the scope of the present invention.
化合物的结构通过核磁共振波谱(
1H NMR)或质谱(MS)进行确证。
The structures of the compounds were confirmed by nuclear magnetic resonance spectroscopy ( 1 H NMR) or mass spectrometry (MS).
化学位移(δ)以百万分之一(ppm)为单位给出。
1HNMR的测定在Bruker BioSpin GmbH 400核磁仪上进行,测试溶剂为氘代甲醇(CD
3OD)、氘代氯仿(CDCl
3)或六氘代二甲基亚砜(DMSO-d
6),内标为四甲基硅烷(TMS)。
Chemical shifts (δ) are given in parts per million (ppm). The determination of 1 HNMR was carried out on a Bruker BioSpin GmbH 400 nuclear magnetic instrument, and the test solvent was deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or hexadeuterated dimethyl sulfoxide (DMSO-d 6 ). Designated as tetramethylsilane (TMS).
LC-MS的测定在岛津LC-MS-2020液质联用仪(生产商:岛津,型号:岛津LC-MS-2020)上进行。The measurement of LC-MS was performed on a Shimadzu LC-MS-2020 liquid mass spectrometer (manufacturer: Shimadzu, model: Shimadzu LC-MS-2020).
制备高效液相色谱法使用waters 2767(waters sunfire,C18,19×250mm 10um色谱柱)进行。Preparative high performance liquid chromatography was performed using waters 2767 (waters sunfire, C18, 19×250mm 10um chromatographic column).
薄层色谱法(TLC)使用黄海牌HSGF 254(5×20em)硅胶板进行,薄层制备色谱法采用规格为烟台产GF 254(0.4~0.5nm)硅胶板进行。Thin-layer chromatography (TLC) was performed using Huanghai brand HSGF 254 (5×20em) silica gel plates, and thin-layer preparative chromatography was performed using GF 254 (0.4-0.5nm) silica plates produced in Yantai.
采用薄层色谱法(TLC)或LC-MS检测反应,使用的展开剂体系包括二氯甲烷和甲醇体系、正己烷和乙酸乙酯体系以及石油醚和乙酸乙酯体系,根据要分离的化合物的极性不同对展开剂体系进行调节(通过调节溶剂的体积比或者加入三乙胺等进行)。The reaction was detected by thin layer chromatography (TLC) or LC-MS, and the developing solvent systems used included dichloromethane and methanol system, n-hexane and ethyl acetate system, and petroleum ether and ethyl acetate system. Different polarities adjust the developing agent system (by adjusting the volume ratio of the solvent or adding triethylamine, etc.).
微波反应使用BiotageInitiator+(400W,RT~300℃)微波反应器。Microwave reactions BiotageInitiator+ (400W, RT~300°C) microwave reactor was used.
柱色谱法一般使用于成化工200~300目硅胶为固定相。洗脱剂的体系包括二氯甲烷和甲醇体系和正己烷和乙酸乙酯体系,根据要分离的化合物的极性不同对洗脱剂体系进行调节(通过调节溶剂的体积比或者加入三乙胺等进行)。Column chromatography is generally used in Chenghua 200-300 mesh silica gel as the stationary phase. The eluent system includes dichloromethane and methanol system and n-hexane and ethyl acetate system, and the eluent system is adjusted according to the polarity of the compound to be separated (by adjusting the volume ratio of the solvent or adding triethylamine, etc. conduct).
如在实施例中无特殊说明,反应的温度为室温(20℃~30℃)。Unless otherwise specified in the examples, the reaction temperature is room temperature (20°C to 30°C).
实施例中所使用的试剂购自Acros Organics、Aldrich Chemical Company或上海毕得医药科技有限公司等公司。The reagents used in the examples were purchased from companies such as Acros Organics, Aldrich Chemical Company or Shanghai Bide Pharmaceutical Technology Co., Ltd.
本发明中的缩写具有以下含义:Abbreviations in the present invention have the following meanings:
缩写abbreviation | 含义meaning |
CCl 4 CCl 4 | 四氯化碳carbon tetrachloride |
DIEA/DIPEADIEA/DIPEA | N,N-二异丙基乙胺N,N-Diisopropylethylamine |
DMSODMSO | 二甲基亚砜dimethyl sulfoxide |
EDCEDC | 1,2-二氯乙烷1,2-Dichloroethane |
FeFe | 铁iron |
HATUHATU | O-(7-氮杂苯并三唑-1-基)-N,N,N’,N’-四甲基脲六氟磷酸盐O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethylurea hexafluorophosphate |
HClHCl | 盐酸hydrochloric acid |
H 2O H 2 O | 水water |
K 2CO 3 K 2 CO 3 | 碳酸钾Potassium carbonate |
MeOHMeOH | 甲醇methanol |
MeONaMeONa | 甲醇钠Sodium methoxide |
NaBH 3CN NaBH 3 CN | 氰基硼氢化钠Sodium cyanoborohydride |
NH 4Cl NH4Cl | 氯化铵Ammonium chloride |
Pd(PPh 3) 4 Pd(PPh 3 ) 4 | 四(三苯基膦)钯Tetrakis(triphenylphosphine)palladium |
PPh 3 PPh 3 | 三苯基膦Triphenylphosphine |
TLCTLC | 薄层色谱法thin layer chromatography |
r.t./rtr.t./rt | 室温room temperature |
ZnCl 2 ZnCl 2 | 氯化锌Zinc chloride |
实施例1:(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-6-环丁基-2-甲基-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(化合物301)的制备Example 1: (R)-N-(1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)-6-cyclobutyl-2-methyl-5,6,7, Preparation of 8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (Compound 301)
第一步:将乙脒(2.4g,23.1mmol)溶解在甲醇(50mL)中,加入甲醇钠(3.2g,58.4mmol)和1-(叔丁基)3-甲基4-氧代哌啶-1,3-二甲酸酯(5.0g,19.5mmol)。将反应液于60℃搅拌6小时。将反应物冷却,减压浓缩,加水稀释(100mL),向体系中加入盐酸(2M)调pH值到中性,乙酸乙酯萃取(2x100mL),将有机相减压浓缩,得到化合物301-1(5.0g),其为白色固体,收率96%。ESI-MS:266[M+H]
+.
Step 1: Dissolve acetamidine (2.4 g, 23.1 mmol) in methanol (50 mL), add sodium methoxide (3.2 g, 58.4 mmol) and 1-(tert-butyl) 3-methyl 4-oxopiperidine -1,3-Dicarboxylate (5.0 g, 19.5 mmol). The reaction solution was stirred at 60°C for 6 hours. The reactant was cooled, concentrated under reduced pressure, diluted with water (100 mL), added hydrochloric acid (2M) to the system to adjust the pH to neutral, extracted with ethyl acetate (2×100 mL), and the organic phase was concentrated under reduced pressure to obtain compound 301-1 (5.0 g) as a white solid, 96% yield. ESI-MS: 266[M+H] + .
第二步:将301-1(5.0g,18.9mmol)溶于1,2-二氯乙烷(70mL),加入四氯化碳(3.2g,21.1mmol)和三苯基膦(5.5g,21.1mmol),将反应物在70℃下反应8小时。将反应物冷却,将反应液减压浓缩,将浓缩物通过柱色谱法(乙酸乙酯∶石油醚=0-60%)分离纯化,得到化合物301-2(4.7g),其为淡黄色固体,收率89%。ESI-MS:284[M+H]
+.
Step 2: Dissolve 301-1 (5.0 g, 18.9 mmol) in 1,2-dichloroethane (70 mL), add carbon tetrachloride (3.2 g, 21.1 mmol) and triphenylphosphine (5.5 g, 21.1 mmol), the reaction was reacted at 70°C for 8 hours. The reactant was cooled, the reaction solution was concentrated under reduced pressure, and the concentrate was separated and purified by column chromatography (ethyl acetate:petroleum ether=0-60%) to obtain compound 301-2 (4.7g) as a pale yellow solid , the yield is 89%. ESI-MS: 284[M+H] + .
第三步:将301-2(2.0g,7.1mmol)溶于二甲基亚砜(20mL),加入(R)-1-(3-硝基-5-(三氟甲基)苯基)乙-1-胺盐酸盐(2.3g,8.5mmol)和N,N-二异丙基乙胺(2.7g,21.3mmol),将反应液于150℃下搅拌16小时。将反应物冷却,加水稀释(50mL),乙酸乙酯萃取(100mL),将有机相减压浓缩,将浓缩物通过柱色谱法(甲醇∶二氯甲烷=0-8%)分离纯化,得到化合物301-3(1.7g),其为淡黄色固体,收率50%。ESI-MS:482[M+H]
+.
The third step: Dissolve 301-2 (2.0 g, 7.1 mmol) in dimethyl sulfoxide (20 mL), add (R)-1-(3-nitro-5-(trifluoromethyl)phenyl) Ethan-1-amine hydrochloride (2.3 g, 8.5 mmol) and N,N-diisopropylethylamine (2.7 g, 21.3 mmol), and the reaction solution was stirred at 150° C. for 16 hours. The reactant was cooled, diluted with water (50 mL), extracted with ethyl acetate (100 mL), the organic phase was concentrated under reduced pressure, and the concentrate was separated and purified by column chromatography (methanol:dichloromethane=0-8%) to obtain the compound 301-3 (1.7 g) as a pale yellow solid, 50% yield. ESI-MS: 482[M+H] + .
第四步:将301-3(1.7g,3.5mmol)溶于二氧六环(20mL),加入盐酸(4M,二氧六环中的溶液)(5mL),将反应液在室温下搅拌,TLC监控原料反应完全,减压浓缩去除溶剂得化合物301-4(1.3g), 其为白色固体,收率90%。ESI-MS:382[M+H]
+.
The fourth step: 301-3 (1.7g, 3.5mmol) was dissolved in dioxane (20mL), hydrochloric acid (4M, solution in dioxane) (5mL) was added, and the reaction solution was stirred at room temperature, The reaction of the raw materials was monitored by TLC, and the solvent was removed by concentration under reduced pressure to obtain compound 301-4 (1.3 g), which was a white solid with a yield of 90%. ESI-MS: 382[M+H] + .
第五步:将301-4(150mg,0.4mmol)溶于甲醇(5mL),加入环丁酮(50mg,0.7mmol)、无水氯化锌(145mg,1.0mmol)和氰基硼氢化钠(68mg,1.0mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,得化合物301-5(120mg),其为黄色固体,收率76%。ESI-MS:436[M+H]
+.
The fifth step: dissolve 301-4 (150mg, 0.4mmol) in methanol (5mL), add cyclobutanone (50mg, 0.7mmol), anhydrous zinc chloride (145mg, 1.0mmol) and sodium cyanoborohydride ( 68 mg, 1.0 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 301-5 (120 mg) as a yellow solid with a yield of 76%. ESI-MS: 436[M+H] + .
第六步:将301-5(120mg,0.3mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(157mg,2.8mmol)和氯化铵(150mg,2.8mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-6-环丁基-2-甲基-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(53.79mg),其为白色固体,收率49%。ESI-MS:406[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 6.83(s,1H),6.79-6.77(m,2H),6.67(s,1H),5.52-5.50(m,2H),5.40-5.34(m,1H),3.34-3.31(m,2H),3.18(s,3H),2.98-2.94(m,2H),2.92(s,3H),2.10-2.07(m,2H),1.92-1.87(m,2H),1.72-1.66(m,2H),1.45(d,J=4.0Hz,3H)。
Step 6: Dissolve 301-5 (120mg, 0.3mmol) in ethanol (5mL) and water (2mL), add iron powder (157mg, 2.8mmol) and ammonium chloride (150mg, 2.8mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-N-(1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-6-cyclobutyl-2-methyl -5,6,7,8-Tetrahydropyrido[4,3-d]pyrimidin-4-amine (53.79 mg) as a white solid, 49% yield. ESI-MS: 406[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 6.83 (s, 1H), 6.79-6.77 (m, 2H), 6.67 (s, 1H), 5.52-5.50 (m, 2H), 5.40-5.34 (m, 1H), 3.34-3.31 (m, 2H), 3.18 (s, 3H), 2.98-2.94 (m, 2H), 2.92 (s, 3H), 2.10-2.07 (m, 2H), 1.92-1.87 (m, 2H), 1.72-1.66 (m, 2H), 1.45 (d, J=4.0 Hz, 3H).
实施例2:(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-2-甲基-6-(四氢-2H-吡喃-4-基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(化合物302)的制备Example 2: (R)-N-(1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)-2-methyl-6-(tetrahydro-2H-pyran-4 -yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (Compound 302) Preparation
第一步:将301-4(130mg,0.3mmol)溶于甲醇(5mL),加入四氢-4H-吡喃-4-酮(60mg,0.6mmol)、无水氯化锌(121mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,得化合物302-1(110mg),其为黄色固体,收率76%。ESI-MS:466[M+H]
+.
The first step: dissolve 301-4 (130mg, 0.3mmol) in methanol (5mL), add tetrahydro-4H-pyran-4-one (60mg, 0.6mmol), anhydrous zinc chloride (121mg, 0.9mmol) ) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction solution was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 302-1 (110 mg) as a yellow solid with a yield of 76%. ESI-MS: 466[M+H] + .
第二步:将302-1(110mg,0.2mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(135mg,2.4mmol)和氯化铵(129mg,2.4mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-2-甲基-6-(四氢-2H-吡喃-4-基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(38.11mg),其为白色固体,收率36%。ESI-MS:436[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 6.83(s,1H),6.79-6.76(m,2H),6.68(s,1H),5.53-5.51(m,2H),5.41-5.33(m,1H),3.97-3.93(m,2H),3.39(s,2H),3.36-3.30(m,2H),2.76-2.73(m,2H),2.67-2.61(m,1H),2.58-2.56(m,2H),2.23(s,3H),1.83-1.80(m,2H),1.63-1.54(m,2H),1.45(d,J=4.0Hz,3H)。
Step 2: Dissolve 302-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-N-(1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-2-methyl-6-(tetrahydro -2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (38.11 mg) as a white solid, 36% yield. ESI-MS: 436[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 6.83 (s, 1H), 6.79-6.76 (m, 2H), 6.68 (s, 1H), 5.53-5.51 (m, 2H), 5.41-5.33 (m, 1H), 3.97-3.93 (m, 2H), 3.39 (s, 2H), 3.36-3.30 (m, 2H), 2.76-2.73 (m, 2H), 2.67-2.61 (m, 1H), 2.58 -2.56 (m, 2H), 2.23 (s, 3H), 1.83-1.80 (m, 2H), 1.63-1.54 (m, 2H), 1.45 (d, J=4.0 Hz, 3H).
实施例3:(R)-6-环丁基-N-(1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)-2-甲基-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(化合物303)的制备Example 3: (R)-6-Cyclobutyl-N-(1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)-2- Preparation of methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (compound 303)
第一步:将化合物301-2(2.0g,7.1mmol)溶于二甲基亚砜(20mL),加入(R)-1-(5-溴噻吩-2-基)乙-1-胺盐酸盐(2.0g,8.5mmol)和N,N-二异丙基乙胺(2.7g,21.3mmol),将反应液于150℃下搅拌16小时。将反应物冷却,加水稀释(50mL),乙酸乙酯萃取(100mL),将有机相减压浓缩,将浓缩物通过柱色谱法(甲醇∶二氯甲烷=0-8%)分离纯化,得到化合物303-1(1.7g),其为淡黄色固体,收率53%。ESI-MS:453[M+H]
+.
The first step: Compound 301-2 (2.0 g, 7.1 mmol) was dissolved in dimethyl sulfoxide (20 mL), and (R)-1-(5-bromothiophen-2-yl) ethan-1-amine salt was added acid (2.0 g, 8.5 mmol) and N,N-diisopropylethylamine (2.7 g, 21.3 mmol), and the reaction solution was stirred at 150° C. for 16 hours. The reactant was cooled, diluted with water (50 mL), extracted with ethyl acetate (100 mL), the organic phase was concentrated under reduced pressure, and the concentrate was separated and purified by column chromatography (methanol:dichloromethane=0-8%) to obtain the compound 303-1 (1.7 g) as a pale yellow solid, 53% yield. ESI-MS: 453[M+H] + .
第二步:将303-1(1.7g,3.8mmol)溶于二氧六环\水(5∶1)(30mL),加入(2-((二甲基氨基)甲基)苯基)硼酸(1.0g,5.7mmol)、四(三苯基膦)钯(462mg,0.4mmol)和碳酸钾(1.6g,11.4mmol),将反应液于100℃下搅拌16小时。将反应物冷却,过滤,将滤液减压浓缩,加水稀释(50mL),乙酸乙酯萃取(100mL),将有机相减压浓缩,将浓缩物通过柱色谱法(甲醇∶二氯甲烷=0-8%)分离纯化,得到化合物303-2 (1.5g),其为淡黄色固体,收率78%。ESI-MS:508[M+H]
+.
Step 2: Dissolve 303-1 (1.7g, 3.8mmol) in dioxane\water (5:1) (30mL), add (2-((dimethylamino)methyl)phenyl)boronic acid (1.0 g, 5.7 mmol), tetrakis(triphenylphosphine)palladium (462 mg, 0.4 mmol) and potassium carbonate (1.6 g, 11.4 mmol), and the reaction solution was stirred at 100° C. for 16 hours. The reactant was cooled, filtered, the filtrate was concentrated under reduced pressure, diluted with water (50 mL), extracted with ethyl acetate (100 mL), the organic phase was concentrated under reduced pressure, and the concentrate was subjected to column chromatography (methanol:dichloromethane=0- 8%) was isolated and purified to obtain compound 303-2 (1.5 g) as a pale yellow solid with a yield of 78%. ESI-MS: 508[M+H] + .
第三步:将303-2(1.7g,3.0mmol)溶于二氧六环(20mL),加入盐酸(4M,二氧六环的溶液)(5mL),将反应液在室温下搅拌,TLC监控原料反应完全,减压浓缩去除溶剂得化合物303-3(1.0g),其为白色固体,收率83%。ESI-MS:408[M+H]
+.
The third step: Dissolve 303-2 (1.7 g, 3.0 mmol) in dioxane (20 mL), add hydrochloric acid (4M, a solution in dioxane) (5 mL), and stir the reaction solution at room temperature. TLC After monitoring the reaction of the raw materials, the solvent was removed by concentration under reduced pressure to obtain compound 303-3 (1.0 g) as a white solid with a yield of 83%. ESI-MS: 408[M+H] + .
第四步:将303-3(120mg,0.3mmol)溶于甲醇(5mL),加入环丁酮(43mg,0.6mmol)、无水氯化锌(130mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-6-环丁基-N-(1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)-2-甲基-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(52.76mg),其为白色固体,收率38%。ESI-MS:462[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 7.43(d,J=8.0Hz,1H),7.37(d,J=8.0Hz,1H),7.35-7.28(m,2H),7.15(d,J=4.0Hz,1H),7.00-6.96(m,2H),5.79-5.76(m,1H),3.37(s,2H),3.31(s,2H),3.19-3.11(m,2H),2.97-2.90(m,1H),2.52-2.51(m,2H),2.31(s,3H),2.13(s,6H),2.07-2.05(m,2H),1.90-1.83(m,2H),1.70-1.64(m,2H),1.61(d,J=4.0Hz,3H)。
The fourth step: dissolve 303-3 (120mg, 0.3mmol) in methanol (5mL), add cyclobutanone (43mg, 0.6mmol), anhydrous zinc chloride (130mg, 0.9mmol) and sodium cyanoborohydride ( 61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to obtain (R)-6- Cyclobutyl-N-(1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)-2-methyl-5,6,7,8 - Tetrahydropyrido[4,3-d]pyrimidin-4-amine (52.76 mg) as a white solid, 38% yield. ESI-MS: 462[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 7.43 (d, J=8.0 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.35-7.28 (m, 2H), 7.15 ( d, J=4.0Hz, 1H), 7.00-6.96(m, 2H), 5.79-5.76(m, 1H), 3.37(s, 2H), 3.31(s, 2H), 3.19-3.11(m, 2H) , 2.97-2.90(m, 1H), 2.52-2.51(m, 2H), 2.31(s, 3H), 2.13(s, 6H), 2.07-2.05(m, 2H), 1.90-1.83(m, 2H) , 1.70-1.64 (m, 2H), 1.61 (d, J=4.0Hz, 3H).
实施例4:(R)-4-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)-N,N-二甲基环己烷-1-甲酰胺(化合物304)的制备Example 4: (R)-4-(4-((1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-7,8-dihydro Preparation of pyrido[4,3-d]pyrimidin-6(5H)-yl)-N,N-dimethylcyclohexane-1-carboxamide (compound 304)
第一步:将301-4(130mg,0.3mmol)溶于甲醇(5mL),加入N,N-二甲基-4-氧代环己烷-1-甲酰胺(101mg,0.6mmol)、无水氯化锌(121mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,得化合物304-1(110mg),其为黄色固体,收率69%。ESI-MS:535[M+H]
+.
The first step: Dissolve 301-4 (130 mg, 0.3 mmol) in methanol (5 mL), add N,N-dimethyl-4-oxocyclohexane-1-carboxamide (101 mg, 0.6 mmol), no Aqueous zinc chloride (121 mg, 0.9 mmol) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 304-1 (110 mg) as a yellow solid with a yield of 69%. ESI-MS: 535[M+H] + .
第二步:将304-1(110mg,0.2mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(135mg,2.4mmol)和氯化铵(129mg,2.4mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-4-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)-N,N-二甲基环己烷-1-甲酰胺(52.33mg),其为白色固体,收率52%。ESI-MS:505[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 9.01(d,J=8.0Hz,1H),6.87(s,2H),6.76(s,1H),5.55-5.47(m,1H),4.22(s,2H),3.75-3.22(m,4H),3.03(s,3H),2.81(s,3H),2.63-2.58(m,1H),2.53(s,6H),2.25-2.23(m,2H),1.90-1.87(m,2H),1.67-1.61(m,2H),1.55(d,J=4.0Hz,3H),1.50-1.47(m,2H)。
Step 2: Dissolve 304-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-4-(4-((1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl -7,8-Dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-N,N-dimethylcyclohexane-1-carboxamide (52.33 mg) as a white solid , the yield is 52%. ESI-MS: 505[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.01 (d, J=8.0 Hz, 1H), 6.87 (s, 2H), 6.76 (s, 1H), 5.55-5.47 (m, 1H), 4.22(s, 2H), 3.75-3.22(m, 4H), 3.03(s, 3H), 2.81(s, 3H), 2.63-2.58(m, 1H), 2.53(s, 6H), 2.25-2.23( m, 2H), 1.90-1.87 (m, 2H), 1.67-1.61 (m, 2H), 1.55 (d, J=4.0 Hz, 3H), 1.50-1.47 (m, 2H).
实施例5:(R)-4-(4-((1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)-N,N-二甲基环己烷-1-甲酰胺(化合物305)的制备Example 5: (R)-4-(4-((1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2- Preparation of methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-N,N-dimethylcyclohexane-1-carboxamide (compound 305)
将化合物303-3(120mg,0.3mmol)溶于甲醇(5mL),加入N,N-二甲基-4-氧代环己烷-1-甲酰胺(101mg,0.6mmol)、无水氯化锌(130mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-4-(4-((1-(5-(2-((二甲基氨基)甲基)苯 基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)-N,N-二甲基环己烷-1-甲酰胺(135.88mg),其为白色固体,收率81%。ESI-MS:561[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm9.03(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),7.56-7.49(m,2H),7.42(d,J=8.0Hz,1H),7.18(d,J=4.0Hz,1H),7.11(d,J=4.0Hz,1H),5.94-5.87(m,1H),4.43(s,2H),4.17-4.16(m,2H),3.42-3.41(m,2H),3.08-3.00(m,6H),2.81(s,3H),2.78-2.66(m,6H),2.55(s,3H),2.15-1.91(m,2H),1.93-1.86(m,3H),1.71(d,J=4.0Hz,3H),1.72-1.62(m,2H),1.59-1.50(m,2H)。
Compound 303-3 (120 mg, 0.3 mmol) was dissolved in methanol (5 mL), N,N-dimethyl-4-oxocyclohexane-1-carboxamide (101 mg, 0.6 mmol) was added, and anhydrous chlorination Zinc (130 mg, 0.9 mmol) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to obtain (R)-4- (4-((1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2-methyl-7,8-dihydropyridine and [4,3-d]pyrimidin-6(5H)-yl)-N,N-dimethylcyclohexane-1-carboxamide (135.88 mg) as a white solid, 81% yield. ESI-MS: 561[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.03 (d, J=8.0 Hz, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.56-7.49 (m, 2H), 7.42 (d, J=8.0Hz, 1H), 7.18 (d, J=4.0Hz, 1H), 7.11 (d, J=4.0Hz, 1H), 5.94-5.87 (m, 1H), 4.43 (s, 2H) , 4.17-4.16(m, 2H), 3.42-3.41(m, 2H), 3.08-3.00(m, 6H), 2.81(s, 3H), 2.78-2.66(m, 6H), 2.55(s, 3H) , 2.15-1.91 (m, 2H), 1.93-1.86 (m, 3H), 1.71 (d, J=4.0Hz, 3H), 1.72-1.62 (m, 2H), 1.59-1.50 (m, 2H).
实施例6:(R)-1-(4-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(化合物306)的制备Example 6: (R)-1-(4-(4-((1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-7,8 Preparation of -dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (Compound 306)
第一步:将化合物301-4(130mg,0.3mmol)溶于甲醇(5mL),加入1-乙酰基哌啶-4-酮(85mg,0.6mmol)、无水氯化锌(121mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,得化合物306-1(130mg),其为黄色固体,收率86%。ESI-MS:507[M+H]
+.
The first step: Compound 301-4 (130 mg, 0.3 mmol) was dissolved in methanol (5 mL), 1-acetylpiperidin-4-one (85 mg, 0.6 mmol), anhydrous zinc chloride (121 mg, 0.9 mmol) were added ) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction solution was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 306-1 (130 mg) as a yellow solid with a yield of 86%. ESI-MS: 507[M+H] + .
第二步:将306-1(130mg,0.3mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(135mg,2.4mmol)和氯化铵(129mg,2.4mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-1-(4-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(88.72mg),其为白色固体,收率73%。ESI-MS:477[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 8.82(d,J=8.0Hz,1H),6.85(s,2H),6.76(s,1H),5.54-5.47(m,1H),4.59-4.55(m,1H),4.12(s,2H),4.04-4.00(m,1H),3.57-3.50(m,2H),3.11-3.55(m,3H),2.59-2.50(m,7H),2.12-2.09(m,2H),2.03(s,3H),1.70-1.67(m,2H),1.54(d,J=4.0Hz,3H)。
Step 2: Dissolve 306-1 (130mg, 0.3mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-1-(4-(4-((1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2 -Methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (88.72 mg) as a white solid, Yield 73%. ESI-MS: 477[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 8.82 (d, J=8.0 Hz, 1H), 6.85 (s, 2H), 6.76 (s, 1H), 5.54-5.47 (m, 1H), 4.59-4.55(m, 1H), 4.12(s, 2H), 4.04-4.00(m, 1H), 3.57-3.50(m, 2H), 3.11-3.55(m, 3H), 2.59-2.50(m, 7H) ), 2.12-2.09 (m, 2H), 2.03 (s, 3H), 1.70-1.67 (m, 2H), 1.54 (d, J=4.0Hz, 3H).
实施例7:(R)-1-(4-(4-((1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(化合物307)的制备Example 7: (R)-1-(4-(4-((1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino) Preparation of -2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (Compound 307)
将化合物303-3(100mg,0.3mmol)溶于甲醇(5mL),加入1-乙酰基哌啶-4-酮(71mg,0.5mmol)、无水氯化锌(116mg,0.8mmol)和氰基硼氢化钠(54mg,0.8mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-1-(4-(4-((1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(30.64mg),其为白色固体,收率23%。ESI-MS:533[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 9.70(br,1H),7.69(d,J=8.0Hz,1H),7.56-7.49(m,2H),7.42(d,J=8.0Hz,1H),7.16(d,J=4.0Hz,1H),7.08(d,J=4.0Hz,1H),5.91-5.84(m,1H),4.55-4.52(m,1H),4.43(s,2H),4.00-3.97(m,4H),3.44-3.30(m,2H),3.10-3.03(m,1H),2.97(s,2H),2.67-2.66(m,4H),2.58-2.50(m,7H),2.04-2.01(m,4H),1.69(d,J=4.0Hz,3H),1.66-1.52(m,2H)。
Compound 303-3 (100 mg, 0.3 mmol) was dissolved in methanol (5 mL), 1-acetylpiperidin-4-one (71 mg, 0.5 mmol), anhydrous zinc chloride (116 mg, 0.8 mmol) and cyano were added Sodium borohydride (54 mg, 0.8 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to obtain (R)-1- (4-(4-((1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2-methyl-7,8- Dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (30.64 mg) as a white solid, 23% yield. ESI-MS: 533[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.70 (br, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.56-7.49 (m, 2H), 7.42 (d, J=8.0 Hz, 1H), 7.16 (d, J=4.0Hz, 1H), 7.08 (d, J=4.0Hz, 1H), 5.91-5.84 (m, 1H), 4.55-4.52 (m, 1H), 4.43 (s , 2H), 4.00-3.97(m, 4H), 3.44-3.30(m, 2H), 3.10-3.03(m, 1H), 2.97(s, 2H), 2.67-2.66(m, 4H), 2.58-2.50 (m, 7H), 2.04-2.01 (m, 4H), 1.69 (d, J=4.0 Hz, 3H), 1.66-1.52 (m, 2H).
实施例8:(R)-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)(四氢-2H-吡喃-4-基)甲酮(化合物308)的制备Example 8: (R)-(4-((1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-7,8-dihydropyrido Preparation of [4,3-d]pyrimidin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone (Compound 308)
第一步:将四氢-2H-吡哺-4-羧酸(40mg,0.9mmol)溶于N,N-二甲基甲酰胺(3mL),加入HATU(137mg,0.4mmol)、N,N-二异丙基乙胺(116mg,0.9mmol)和化合物301-4(130mg,0.3mmol),将反应液于室温下搅拌15小时。加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,得化合物308-1(110mg),其为黄色固体,收率74%。ESI-MS:494[M+H]
+.
Step 1: Dissolve tetrahydro-2H-pyridine-4-carboxylic acid (40 mg, 0.9 mmol) in N,N-dimethylformamide (3 mL), add HATU (137 mg, 0.4 mmol), N,N - Diisopropylethylamine (116 mg, 0.9 mmol) and compound 301-4 (130 mg, 0.3 mmol), the reaction solution was stirred at room temperature for 15 hours. It was diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 308-1 (110 mg) as a yellow solid with a yield of 74%. ESI-MS: 494[M+H] + .
第二步:将308-1(110mg,0.2mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(135mg,2.4mmol)和氯化铵(129mg,2.4mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-(4-((1-(3-氨基-5-(三氟甲基)苯基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)(四氢-2H-吡喃-4-基)甲酮(68.34mg),其为白色固体,收率67%。ESI-MS:494[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 9.00(d,J=8.0Hz,1H),6.90(s,1H),6.85(s,1H),6.75(s,1H),5.57-5.49(m,1H),4.52-4.49(m,1H),4.44(s,2H),3.88-3.84(m,4H),3.45-3.39(m,2H),3.05-3.01(m,1H),2.99-2.83(m,2H),2.72-2.71(m,1H),2.51(s,3H),1.63-1.53(m,7H)。
Step 2: Dissolve 308-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-(4-((1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-7 , 8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone (68.34 mg) as a white solid, yield 67%. ESI-MS: 494[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.00 (d, J=8.0 Hz, 1H), 6.90 (s, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 5.57- 5.49(m, 1H), 4.52-4.49(m, 1H), 4.44(s, 2H), 3.88-3.84(m, 4H), 3.45-3.39(m, 2H), 3.05-3.01(m, 1H), 2.99-2.83 (m, 2H), 2.72-2.71 (m, 1H), 2.51 (s, 3H), 1.63-1.53 (m, 7H).
实施例9:(R)-(4-((1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)(四氢-2H-吡喃-4-基)甲酮(化合物309)的制备Example 9: (R)-(4-((1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2-methyl Preparation of -7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone (Compound 309)
将四氢-2H-吡喃-4-羧酸(40mg,0.9mmol)溶于N,N-二甲基甲酰胺(3mL),加入HATU(137mg,0.4mmol)、N,N-二异丙基乙胺(116mg,0.9mmol)和化合物303-3(100mg,0.3mmol),将反应液于室温下搅拌15小时。加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-(4-((1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)(四氢-2H-吡喃-4-基)甲酮(66.78mg),其为白色固体,收率51%。ESI-MS:520[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 9.76(br,1H),7.70(d,J=8.0Hz,1H),7.51-7.48(m,2H),7.44(d,J=8.0Hz,1H),7.16(d,J=4.0Hz,1H),7.09(d,J=4.0Hz,1H),5.92-5.88(m,1H),4.51-4.31(m,5H),4.92-3.77(m,5H),3.05-3.00(m,1H),2.88-2.87(m,2H),2.54(s,6H),2.51(s,3H),1.71(d,J=8.0Hz,3H),1.63-1.57(m,4H)。
Tetrahydro-2H-pyran-4-carboxylic acid (40 mg, 0.9 mmol) was dissolved in N,N-dimethylformamide (3 mL), HATU (137 mg, 0.4 mmol), N,N-diisopropyl were added Ethylamine (116 mg, 0.9 mmol) and compound 303-3 (100 mg, 0.3 mmol), the reaction solution was stirred at room temperature for 15 hours. Diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to give (R)-(4-((1-(5-( 2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2-methyl-7,8-dihydropyrido[4,3-d]pyrimidine-6 (5H)-yl)(tetrahydro-2H-pyran-4-yl)methanone (66.78 mg) as a white solid, 51% yield. ESI-MS: 520[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.76 (br, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.51-7.48 (m, 2H), 7.44 (d, J=8.0 Hz, 1H), 7.16 (d, J=4.0Hz, 1H), 7.09 (d, J=4.0Hz, 1H), 5.92-5.88 (m, 1H), 4.51-4.31 (m, 5H), 4.92-3.77 (m, 5H), 3.05-3.00 (m, 1H), 2.88-2.87 (m, 2H), 2.54 (s, 6H), 2.51 (s, 3H), 1.71 (d, J=8.0Hz, 3H), 1.63-1.57 (m, 4H).
实施例10:(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-2-甲基-6-((四氢-2H-吡喃-4-基)甲基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(化合物310)的制备Example 10: (R)-N-(1-(3-Amino-5-(trifluoromethyl)phenyl)ethyl)-2-methyl-6-((tetrahydro-2H-pyran- Preparation of 4-yl)methyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (Compound 310)
第一步:将化合物301-4(130mg,0.3mmol)溶于甲醇(5mL),加入四氢-2H-吡喃-4-甲醛(68mg,0.6mmol)、无水氯化锌(121mg,0.9mmol)和氰基硼氢化钠(61mg,0.9mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相 减压浓缩,得化合物310-1(110mg),其为黄色固体,收率76%。ESI-MS:480[M+H]
+.
The first step: Compound 301-4 (130 mg, 0.3 mmol) was dissolved in methanol (5 mL), tetrahydro-2H-pyran-4-carbaldehyde (68 mg, 0.6 mmol), anhydrous zinc chloride (121 mg, 0.9 mmol) were added mmol) and sodium cyanoborohydride (61 mg, 0.9 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), and the organic phase was concentrated under reduced pressure to obtain compound 310-1 (110 mg) as a yellow solid with a yield of 76%. ESI-MS: 480[M+H] + .
第二步:将310-1(110mg,0.2mmol)溶于乙醇(5mL)和水(2mL),加入铁粉(135mg,2.4mmol)和氯化铵(129mg,2.4mmol),将反应液于90℃下搅拌2小时。将反应物冷却,过滤,将滤饼用乙酸乙酯洗涤,将滤液减压浓缩,将浓缩物用水(10mL)稀释,用乙酸乙酯萃取(2x10mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法分离纯化,得(R)-N-(1-(3-氨基-5-(三氟甲基)苯基)乙基)-2-甲基-6-((四氢-2H-吡喃-4-基)甲基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(66.47mg),其为白色固体,收率67%。ESI-MS:450[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 8.96(d,J=8.0Hz,1H),6.87(s,1H),6.85(s,1H),6.75(s,1H),5.53-5.49(m,1H),4.14-4.13(m,2H),3.89-3.85(m,2H),3.46-3.30(m,4H),3.11-3.04(m,4H),2.52.2.50(m,4H),2.14-2.13(m,1H),1.73-1.64(m,2H),1.54(d,J=8.0Hz,3H),1.31-1.20(m,3H)。
Step 2: Dissolve 310-1 (110mg, 0.2mmol) in ethanol (5mL) and water (2mL), add iron powder (135mg, 2.4mmol) and ammonium chloride (129mg, 2.4mmol), put the reaction solution in Stir at 90°C for 2 hours. The reaction was cooled, filtered, the filter cake was washed with ethyl acetate, the filtrate was concentrated under reduced pressure, the concentrate was diluted with water (10 mL), extracted with ethyl acetate (2×10 mL), the organic phase was concentrated under reduced pressure, the concentrate was Separation and purification by high pressure preparative liquid chromatography gave (R)-N-(1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-2-methyl-6-((tetrafluoromethyl) Hydrogen-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (66.47 mg) as a white solid, obtained rate 67%. ESI-MS: 450[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 8.96 (d, J=8.0 Hz, 1H), 6.87 (s, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 5.53- 5.49(m, 1H), 4.14-4.13(m, 2H), 3.89-3.85(m, 2H), 3.46-3.30(m, 4H), 3.11-3.04(m, 4H), 2.52.2.50(m, 4H) ), 2.14-2.13 (m, 1H), 1.73-1.64 (m, 2H), 1.54 (d, J=8.0Hz, 3H), 1.31-1.20 (m, 3H).
实施例11:(R)-N-(1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)-2-甲基-6-((四氢-2H-吡喃-4-基)甲基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(化合物311)的制备Example 11: (R)-N-(1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)-2-methyl-6-( Preparation of (tetrahydro-2H-pyran-4-yl)methyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (compound 311)
将化合物303-3(100mg,0.3mmol)溶于甲醇(5mL),加入四氢-2H-吡喃-4-甲醛(57mg,0.5mmol)、无水氯化锌(116mg,0.8mmol)和氰基硼氢化钠(54mg,0.8mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-N-(1-(5-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)-2-甲基-6-((四氢-2H-吡喃-4-基)甲基)-5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-胺(29.30mg),其为白色固体,收率23%。ESI-MS:506[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 7.44(d,J=8.0Hz,1H),7.38-7.37(m,1H),7.36-7.30(m,2H),7.15(d,J=4.0Hz,1H),7.01-6.96(m,2H),5.80-5.73(m,1H),3.84-3.81(m,3H),3.40-3.34(m,2H),3.29-3.19(m,4H),2.64-2.60(m,4H),2.35-2.34(m,2H),2.31(s,3H),2.14-2.11(m,7H),1.62-1.61(m,6H)。
Compound 303-3 (100 mg, 0.3 mmol) was dissolved in methanol (5 mL), tetrahydro-2H-pyran-4-carbaldehyde (57 mg, 0.5 mmol), anhydrous zinc chloride (116 mg, 0.8 mmol) and cyanide were added sodium borohydride (54 mg, 0.8 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to obtain (R)-N- (1-(5-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)-2-methyl-6-((tetrahydro-2H-pyran-4 -yl)methyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (29.30 mg) as a white solid, 23% yield. ESI-MS: 506[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 7.44 (d, J=8.0 Hz, 1H), 7.38-7.37 (m, 1H), 7.36-7.30 (m, 2H), 7.15 (d, J =4.0Hz, 1H), 7.01-6.96(m, 2H), 5.80-5.73(m, 1H), 3.84-3.81(m, 3H), 3.40-3.34(m, 2H), 3.29-3.19(m, 4H) ), 2.64-2.60 (m, 4H), 2.35-2.34 (m, 2H), 2.31 (s, 3H), 2.14-2.11 (m, 7H), 1.62-1.61 (m, 6H).
实施例12:(R)-1-(4-(4-((1-(4-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(化合物312)的制备Example 12: (R)-1-(4-(4-((1-(4-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino) Preparation of -2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (Compound 312)
第一步:将化合物301-2(1.0g,3.5mmol)溶于二甲基亚砜(20mL),加入(R)-1-(4-溴噻吩-2-基)乙-1-胺盐酸盐(1.0g,4.2mmol)和N,N-二异丙基乙胺(1.4g,10.2mmol),将反应液于150℃下搅拌16小 时。将反应物冷却,加水稀释(50mL),乙酸乙酯萃取(100mL),将有机相减压浓缩,将浓缩物通过柱色谱法(甲醇∶二氯甲烷=0~8%)分离纯化,得到化合物312-1(900mg),其为淡黄色固体,收率56%。ESI-MS:453[M+H]
+.
The first step: Compound 301-2 (1.0 g, 3.5 mmol) was dissolved in dimethyl sulfoxide (20 mL), and (R)-1-(4-bromothiophen-2-yl) ethan-1-amine salt was added acid (1.0 g, 4.2 mmol) and N,N-diisopropylethylamine (1.4 g, 10.2 mmol), and the reaction solution was stirred at 150° C. for 16 hours. The reactant was cooled, diluted with water (50 mL), extracted with ethyl acetate (100 mL), the organic phase was concentrated under reduced pressure, and the concentrate was separated and purified by column chromatography (methanol:dichloromethane=0~8%) to obtain the compound 312-1 (900 mg) as a pale yellow solid, 56% yield. ESI-MS: 453[M+H] + .
第二步:将312-1(900mg,2.0mmol)溶于二氧六环\水(5∶1)(15mL),加入(2-((二甲基氨基)甲基)苯基)硼酸(534mg,3.0mmol)、四(三苯基膦)钯(231mg,0.2mmol)和碳酸钾(823mg,6.0mmol),将反应液于100℃下搅拌16小时。将反应物冷却,过滤,将滤液减压浓缩,加水稀释(50mL),乙酸乙酯萃取(100mL),将有机相减压浓缩,将浓缩物通过柱色谱法(甲醇∶二氯甲烷=0~8%)分离纯化,得到化合物312-2(450mg),其为淡黄色固体,收率45%。ESI-MS:508[M+H]
+.
Step 2: Dissolve 312-1 (900 mg, 2.0 mmol) in dioxane\water (5:1) (15 mL), add (2-((dimethylamino)methyl)phenyl)boronic acid ( 534 mg, 3.0 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 0.2 mmol) and potassium carbonate (823 mg, 6.0 mmol), and the reaction solution was stirred at 100°C for 16 hours. The reactant was cooled, filtered, the filtrate was concentrated under reduced pressure, diluted with water (50 mL), extracted with ethyl acetate (100 mL), the organic phase was concentrated under reduced pressure, and the concentrate was subjected to column chromatography (methanol:dichloromethane=0~ 8%) was isolated and purified to obtain compound 312-2 (450 mg) as a pale yellow solid with a yield of 45%. ESI-MS: 508[M+H] + .
第三步:将312-2(450mg,0.9mmol)溶于二氧六环(5mL),加入盐酸(4M,二氧六环中的溶液)(3mL),将反应液在室温下搅拌,TLC监控原料反应完全,减压浓缩去除溶剂得化合物312-3(300mg),其为白色固体,收率82%。ESI-MS:408[M+H]
+.
The third step: Dissolve 312-2 (450 mg, 0.9 mmol) in dioxane (5 mL), add hydrochloric acid (4M, a solution in dioxane) (3 mL), and stir the reaction solution at room temperature. TLC After monitoring the completion of the reaction of the raw materials, the solvent was removed by concentration under reduced pressure to obtain compound 312-3 (300 mg) as a white solid with a yield of 82%. ESI-MS: 408[M+H] + .
第四步:将312-3(100mg,0.3mmol)溶于甲醇(5mL),加入1-乙酰基哌啶-4-酮(71mg,0.5mmol)、无水氯化锌(116mg,0.8mmol)和氰基硼氢化钠(54mg,0.8mmol),将反应液于室温下搅拌15小时。加水淬灭反应,减压浓缩,加水稀释(10mL),用乙酸乙酯萃取(2x20mL),将有机相减压浓缩,将浓缩物通过高压制备液相色谱法纯化,得(R)-1-(4-(4-((1-(4-(2-((二甲基氨基)甲基)苯基)噻吩-2-基)乙基)氨基)-2-甲基-7,8-二氢吡啶并[4,3-d]嘧啶-6(5H)-基)哌啶-1-基)乙-1-酮(58.03mg),其为白色固体,收率48%。ESI-MS:533[M+H]
+。
1H-NMR(400MHz,DMSO-d
6)δ:ppm 9.45(s,1H),7.42-7.40(m,1H),7.39-7.29(m,3H),7.25(s,1H),6.95(d,J=6.0Hz,1H),5.82-5.74(m,1H),4.45-4.41(m,1H),3.89-3.85(m,1H),3.36-3.30(m,5H),3.06-2.99(m,1H),2.77-2.74(m,2H),2.68-2.60(m,1H),2.59-2.57(m,2H),2.30(s,3H),2.12(s,6H),2.00(s,3H),1.86-1.80(m,2H),1.61(d,J=8.0Hz,3H),1.53-1.51(m,2H)。
The fourth step: dissolve 312-3 (100mg, 0.3mmol) in methanol (5mL), add 1-acetylpiperidin-4-one (71mg, 0.5mmol), anhydrous zinc chloride (116mg, 0.8mmol) and sodium cyanoborohydride (54 mg, 0.8 mmol), and the reaction was stirred at room temperature for 15 hours. The reaction was quenched by adding water, concentrated under reduced pressure, diluted with water (10 mL), extracted with ethyl acetate (2×20 mL), the organic phase was concentrated under reduced pressure, and the concentrate was purified by high pressure preparative liquid chromatography to obtain (R)-1- (4-(4-((1-(4-(2-((dimethylamino)methyl)phenyl)thiophen-2-yl)ethyl)amino)-2-methyl-7,8- Dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)piperidin-1-yl)ethan-1-one (58.03 mg) as a white solid, 48% yield. ESI-MS: 533[M+H] + . 1 H-NMR (400 MHz, DMSO-d 6 ) δ: ppm 9.45(s, 1H), 7.42-7.40(m, 1H), 7.39-7.29(m, 3H), 7.25(s, 1H), 6.95(d , J=6.0Hz, 1H), 5.82-5.74(m, 1H), 4.45-4.41(m, 1H), 3.89-3.85(m, 1H), 3.36-3.30(m, 5H), 3.06-2.99(m , 1H), 2.77-2.74(m, 2H), 2.68-2.60(m, 1H), 2.59-2.57(m, 2H), 2.30(s, 3H), 2.12(s, 6H), 2.00(s, 3H ), 1.86-1.80 (m, 2H), 1.61 (d, J=8.0 Hz, 3H), 1.53-1.51 (m, 2H).
生物学测定biological assay
实验例1.KRAS::SOS1 HTRF结合分析Experimental Example 1. KRAS::SOS1 HTRF binding assay
此测定法可用于检查化合物抑制SOS1与KRAS
G12C之间的蛋白-蛋白相互作用的效力。这证明了化合物的分子作用模式。低IC
50值指示SOS1抑制剂化合物在以下这种测定设置中的高效力。
This assay can be used to examine the potency of compounds to inhibit the protein-protein interaction between SOS1 and KRAS G12C . This demonstrates the molecular mode of action of the compound. Low IC50 values indicate high potency of the SOS1 inhibitor compound in this assay setup below.
试剂:Reagents:
·GST-SOS1(aa564-1049),内部生产·GST-SOS1 (aa564-1049), in-house production
·His-KRAS G12C(aa1-169),内部生产·His-KRAS G12C(aa1-169), produced in-house
·MAb Anti-6his-Tb cryptate Gold,购自Cisbio(目录号61HI2TLA)· MAb Anti-6his-Tb cryptate Gold, purchased from Cisbio (Cat. No. 61HI2TLA)
·MAb Anti-GST-XL665,购自Cisbio(目录号61GSTXLA)· MAb Anti-GST-XL665, purchased from Cisbio (Cat. No. 61GSTXLA)
测定板:ProxiPlate-384Plus,购自PerkinElmer(目录号6008280)Assay Plate: ProxiPlate-384Plus, purchased from PerkinElmer (Cat. No. 6008280)
测定缓冲液:PPI,购自Cisbio(目录号61DB10RDF)Assay buffer: PPI, purchased from Cisbio (Cat. No. 61DB10RDF)
测定方案:Assay protocol:
·将待测化合物溶解在DMSO中,配制储备液浓度为10mM,并用DMSO稀释化合物浓度至2mM作为测定起始浓度,对2mM起始浓度化合物溶液连续3倍稀释,共稀释10个浓度,使用Labcyte Echo仪器转移0.1μL各浓度化合物溶液至384孔测定板中(一式两份,双复孔);Dissolve the compound to be tested in DMSO, prepare a stock solution with a concentration of 10 mM, and dilute the compound concentration with DMSO to 2 mM as the starting concentration of the assay, serially dilute the compound solution with a 2 mM starting concentration 3 times, and dilute a total of 10 concentrations, using Labcyte The Echo instrument transferred 0.1 μL of compound solutions of each concentration to a 384-well assay plate (duplicate, double wells);
·向0.1μL化合物溶液中加入5μL特定浓度的His-KRAS G12C,在Eppendorf5810R离心机上以1000rpm离心1min;Add 5 μL of His-KRAS G12C at a specific concentration to 0.1 μL of the compound solution, and centrifuge at 1000 rpm for 1 min on an Eppendorf 5810R centrifuge;
·随后加入5μL特定浓度的GST-SOS1,同样置于Eppendorf 5810R离心机以1000rpm离心1min;Then add 5 μL of GST-SOS1 at a specific concentration, and centrifuge at 1000 rpm for 1 min in an Eppendorf 5810R centrifuge;
·将384孔测定板于25℃孵育15min;·Incubate the 384-well assay plate at 25°C for 15min;
·然后加入10μL MAb Anti-6his-Tb和MAb Anti-GST-XL665混合物,在Eppendorf 5810R离心机上以1000rpm离心1min;10 μL of MAb Anti-6his-Tb and MAb Anti-GST-XL665 mixture were then added and centrifuged at 1000 rpm for 1 min on an Eppendorf 5810R centrifuge;
·384孔测定板于25℃孵育2h;Incubate the 384-well assay plate at 25°C for 2h;
·最后使用Perkin Elmer Envision 2104仪器读板,获得665/615nm信号比值。· Finally use Perkin Elmer Envision 2104 instrument to read the plate to obtain the 665/615nm signal ratio.
每个板含有以下对照:Each plate contains the following controls:
·DMSO+KRAS+SOS1+MAb Anti-6his-Tb+MAb Anti-GST-XL665·DMSO+KRAS+SOS1+MAb Anti-6his-Tb+MAb Anti-GST-XL665
结果计算:Result calculation:
使用4参数回归方程计算和分析IC
50值。测定结果如下表所示。
IC50 values were calculated and analyzed using a 4-parameter regression equation. The measurement results are shown in the table below.
化合物编号Compound number | SOS1-KRAS G12C相互作用测定(IC 50,nM) SOS1-KRAS G12C Interaction Assay ( IC50 , nM) |
301301 | 247.4247.4 |
302302 | 116.5116.5 |
303303 | 136.6136.6 |
304304 | 83.383.3 |
305305 | 86.786.7 |
306306 | 54.354.3 |
307307 | 3232 |
309309 | 124.1124.1 |
311311 | 117.7117.7 |
312312 | 85.485.4 |
除本文中描述的那些外,根据前述描述,本发明的各种修改对本领域技术人员而言会是显而易见的。这样的修改也意图落入所附权利要求书的范围内。本申请中所引用的各参考文献(包括所有专利、专利申请、期刊文章、书籍及任何其它公开)均以其整体援引加入本文。Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application, including all patents, patent applications, journal articles, books, and any other publications, is incorporated by reference in its entirety.
Claims (13)
- 化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(I)的结构:A compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the formula (I )Structure:其中:in:X 1、X 2、X 3和X 4各自独立地选自C=O、CH 2、CHR、C(R) 2和N-L-R 2,优选地,X 1、X 2、X 3和X 4中至少一个为N-L-R 2; X 1 , X 2 , X 3 and X 4 are each independently selected from C=O, CH 2 , CHR, C(R) 2 and NLR 2 , preferably, at least among X 1 , X 2 , X 3 and X 4 One is NLR 2 ;L选自直接键、C 1-6亚烷基、C(=O)、O、S(=O)、S(=O) 2和NR 4; L is selected from direct bond, C1-6 alkylene, C(=O), O, S(=O), S(=O) 2 and NR4 ;环B选自C 3-10烃环、3-10元杂环、C 6-10芳环和5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O); Ring B is selected from C 3-10 hydrocarbon rings, 3-10-membered heterocycles, C 6-10 -membered aromatic rings and 5-14-membered heteroaromatic rings, wherein at most 2 ring members of the hydrocarbon rings and heterocycles are C(= O);R和R 1在每次出现时各自独立地选自卤素、-NH 2、-CN、-NO 2、-OH、-O-C 1-6烷基、C 1-6烷基、卤代C 1-6烷基、C 1-6亚烷基-OH、卤代C 1-6亚烷基-OH、C 2-6烯基、C 2-6炔基、饱和或部分不饱和的C 3-10环烃基、饱和或部分不饱和的3-10元杂环基、C 6-10芳基、5-14元杂芳基和C 6-12芳烷基,所述环烃基和杂环基中至多2个环成员为C(=O),当m大于1和/或n大于1时,两个R 1和/或两个R连同其所连接的原子任选地共同构成C 3-10烃环、3-10元杂环、C 6-10芳环或5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O); R and R 1 are each independently selected at each occurrence from halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, C 1-6 alkyl, halogenated C 1- 6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl, saturated or partially unsaturated C 3-10 Cyclic hydrocarbon groups, saturated or partially unsaturated 3-10 membered heterocyclic groups, C 6-10 aryl groups, 5-14 membered heteroaryl groups and C 6-12 aralkyl groups, among the cyclic hydrocarbon groups and heterocyclic groups at most 2 ring members are C(=O), when m is greater than 1 and/or n is greater than 1, two R 1 and/or two R together with the atoms to which they are attached optionally together form a C 3-10 hydrocarbon ring , 3-10-membered heterocyclic ring, C 6-10 -membered aromatic ring or 5-14-membered heteroaromatic ring, wherein at most 2 ring members in the hydrocarbon ring and the heterocyclic ring are C(=O);R 2选自H、C 1-6烷基、卤代C 1-6烷基、C 1-6亚烷基-OH、卤代C 1-6亚烷基-OH、C 2-6烯基、C 2-6炔基、饱和或部分不饱和的C 3-10环烃基、饱和或部分不饱和的3-10元杂环基、C 6-10芳基、5-14元杂芳基、C 6-12芳烷基、-C(=O)R 5、-OC(=O)R 5、-C(=O)OR 5、-OR 5、-SR 5、-S(=O)R 5、-S(=O) 2R 5、-S(=O) 2NR 5R 6、-NR 5R 6、-C(=O)NR 5R 6、-NR 5-C(=O)R 6、-NR 5-C(=O)OR 6、-NR 5-S(=O) 2-R 6、-NR 5-C(=O)-NR 5R 6、-C 1-6亚烷基-NR 5R 6、-C 1-6亚烷基-O(P=O)(OH) 2和-O-C 1-6亚烷基-NR 5R 6; R 2 is selected from H, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl , C 2-6 alkynyl, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl, -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O) R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 sub Alkyl-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;R 3和R 4各自独立地选自H、卤素、-NH 2、-CN、-NO 2、-OH、-O-C 1-6烷基、-O-(3-10元杂环基)、C 1-6烷基、卤代C 1-6烷基、C 1-6亚烷基-OH、卤代C 1-6亚烷基-OH、C 2-6烯基、C 2-6炔基、饱和或部分不饱和的C 3-10环烃基、饱和或部分不饱和的3-10元杂环基、C 6-10芳基、5-14元杂芳基、C 6-12芳烷基、-C(=O)R 5、-OC(=O)R 5、-C(=O)OR 5、-OR 5、-SR 5、-S(=O)R 5、-S(=O) 2R 5、-S(=O) 2NR 5R 6、-NR 5R 6、-C(=O)NR 5R 6、-NR 5-C(=O)R 6、-NR 5-C(=O)OR 6、-NR 5-S(=O) 2-R 6、-NR 5-C(=O)-NR 5R 6、-C 1-6亚烷基-NR 5R 6、-C 1-6亚烷基-O(P=O)(OH) 2和-O-C 1-6亚烷基-NR 5R 6; R 3 and R 4 are each independently selected from H, halogen, -NH 2 , -CN, -NO 2 , -OH, -OC 1-6 alkyl, -O-(3-10 membered heterocyclyl), C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, C 2-6 alkenyl, C 2-6 alkynyl , saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group, C 6-12 aralkyl group , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O ) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 - C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O)-NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 , -C 1-6 alkylene-O(P=O)(OH) 2 and -OC 1-6 alkylene-NR 5 R 6 ;上述基团在每次出现时各自任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH 2、-CN、-NO 2、C 1-6烷基、C 2-6烯基、C 2-6炔基、C 3-6环烃基、3-10元杂环基、C 6-10芳基、5-14元杂芳基、C 6-12芳烷基、=N-OR 5、-C(=NH)NH 2、-C(=O)R 5、-OC(=O)R 5、-C(=O)OR 5、-OR 5、-SR 5、-S(=O)R 5、-S(=O) 2R 5、-S(=O) 2NR 5R 6、-NR 5R 6、-C(=O)NR 5R 6、-NR 5-C(=O)R 6、-NR 5-C(=O)OR 6、-NR 5-S(=O) 2-R 6、-NR 5-C(=O)-NR 5R 6、-C 1-6亚烷基-NR 5R 6和-O-C 1-6亚烷基-NR 5R 6,所述烷基、环烃基、杂环基、芳基、杂芳基和芳烷基进一步任选地被一个或多个独立地选自下列的取代基取代:卤素、-OH、氧代、-NH 2、-CN、-NO 2、C 1-6烷基、C 3-6环烃基、3-10元杂环基、C 6-10芳基、5-14元杂芳基和C 6-12芳烷基; The above groups are each optionally substituted at each occurrence with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, -NH2 , -CN, -NO2 , C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered heteroaryl, C 6- 12 Aralkyl, =N-OR 5 , -C(=NH)NH 2 , -C(=O)R 5 , -OC(=O)R 5 , -C(=O)OR 5 , -OR 5 , -SR 5 , -S(=O)R 5 , -S(=O) 2 R 5 , -S(=O) 2 NR 5 R 6 , -NR 5 R 6 , -C(=O)NR 5 R 6 , -NR 5 -C(=O)R 6 , -NR 5 -C(=O)OR 6 , -NR 5 -S(=O) 2 -R 6 , -NR 5 -C(=O) -NR 5 R 6 , -C 1-6 alkylene-NR 5 R 6 and -OC 1-6 alkylene-NR 5 R 6 , the alkyl, cyclohydrocarbyl, heterocyclyl, aryl, heterocyclyl Aryl and aralkyl are further optionally substituted with one or more substituents independently selected from halogen, -OH, oxo, -NH2 , -CN, -NO2 , Ci_6alkyl , C 3-6 cyclic hydrocarbon group, 3-10-membered heterocyclic group, C 6-10 aryl group, 5-14-membered heteroaryl group and C 6-12 aralkyl group;R 5和R 6在每次出现时各自独立地选自H、C 1-6烷基、C 3-10环烃基、3-10元杂环基、C 6-10芳基、5-14元杂芳基和C 6-12芳烷基;并且 R 5 and R 6 at each occurrence are each independently selected from H, C 1-6 alkyl, C 3-10 cyclohydrocarbyl, 3-10 membered heterocyclyl, C 6-10 aryl, 5-14 membered Heteroaryl and C 6-12 aralkyl; andm为选自0、1、2、3和4的整数。m is an integer selected from 0, 1, 2, 3 and 4.
- 权利要求1的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(II)的结构:The compound of claim 1 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of formula (II):n为选自0、1、2或3的整数。n is an integer selected from 0, 1, 2 or 3.
- 权利要求1或2的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中L为直接键、-CH 2-或C(=O)。 The compound of claim 1 or 2, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein L is a direct bond, -CH 2 - or C(=O).
- 权利要求1-3中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中,R 2为饱和或部分不饱和的C 3-10环烃基或饱和或部分不饱和的3-10元杂环基,其中所述环烃基和杂环基任选地被一个或多个选自-C(=O)R 5和-C(=O)NR 5R 6的取代基取代; The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro drug, wherein R 2 is a saturated or partially unsaturated C 3-10 cyclic hydrocarbon group or a saturated or partially unsaturated 3-10 membered heterocyclic group, wherein the cyclic hydrocarbon group and the heterocyclic group are optionally composed of one or more substituted with a substituent selected from -C(=O) R5 and -C(=O) NR5R6 ;优选地,R 2为环丁烷基、环己烷基、哌啶基或四氢吡喃基,其任选地被一个或多个选自-C(=O)CH 3和-C(=O)N(CH 3) 2的取代基取代; Preferably, R 2 is cyclobutanyl, cyclohexyl, piperidinyl or tetrahydropyranyl, optionally by one or more selected from -C(=O) CH3 and -C(= O) Substituent substitution of N(CH 3 ) 2 ;
- 权利要求1-4中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中环B为双环[1.1.1]戊烷环、2-氧杂双环[2.1.1]己烷环、苯环或噻吩环,最优选为苯环或噻吩环。The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro medicine, wherein ring B is a bicyclo[1.1.1]pentane ring, a 2-oxabicyclo[2.1.1]hexane ring, a benzene ring or a thiophene ring, most preferably a benzene ring or a thiophene ring.
- 权利要求1-5中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R 1在每次出现时各自独立地选自卤素、-NH 2、C 1-6烷基、卤代C 1-6烷基、C 1-6亚烷基-OH、卤代C 1-6亚烷基-OH、饱和或部分不饱和的C 3-10环烃基、饱和或部分不饱和的3-10元杂环基、C 6-10芳基和5-14元杂芳基,所述亚烷基、烷基、环烃基、杂环基、芳基和杂芳基任选地被一个或多个独立地选自卤素、-OH、C 3-6环烃基、3-10元杂环基、C 6-10芳基和5-14元杂芳基的取代基取代; The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro drug, wherein R 1 at each occurrence is independently selected from halogen, -NH 2 , C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkylene-OH, halogenated C 1-6 alkylene-OH, saturated or partially unsaturated C 3-10 cyclic hydrocarbon group, saturated or partially unsaturated 3-10 membered heterocyclyl, C 6-10 aryl and 5-14 membered heteroaryl , the alkylene, alkyl, cyclohydrocarbyl, heterocyclyl, aryl, and heteroaryl groups are optionally selected from one or more independently halogen, -OH, C 3-6 cyclohydrocarbyl, 3-10 Substituent substitution of membered heterocyclyl, C6-10 aryl and 5-14 membered heteroaryl;当m大于1时,两个R 1连同其所连接的原子任选地共同构成C 3-10烃环、3-10元杂环、C 6-10芳环或5-14元杂芳环,所述烃环和杂环中至多2个环成员为C(=O),并且所述烃环、杂环、芳环和杂芳环任选地被一个或多个卤素取代; When m is greater than 1, the two R 1 together with the atoms to which they are attached optionally together form a C 3-10 hydrocarbon ring, a 3-10 membered heterocyclic ring, a C 6-10 aromatic ring or a 5-14 membered heteroaromatic ring, Up to 2 ring members of the hydrocarbon and heterocycles are C(=O), and the hydrocarbon, heterocycle, aromatic and heteroaromatic rings are optionally substituted with one or more halogens;
- 权利要求1-7中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R 3选自H和C 1-6烷基;优选地,R 3为甲基。 The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro drug, wherein R 3 is selected from H and C 1-6 alkyl; preferably, R 3 is methyl.
- 权利要求1-8中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中R 4选自H和C 1-6烷基;优选地,R 4为H。 The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro drug, wherein R 4 is selected from H and C 1-6 alkyl; preferably, R 4 is H.
- 权利要求1-9中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物具有式(III)的结构:The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro medicine, wherein the compound has the structure of formula (III):
- 权利要求1-10中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,其中所述化合物选自:The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro medicine, wherein the compound is selected from:
- 药物组合物,其包含预防或治疗有效量的权利要求1-11中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药,以及药学上可接受的载体,所述药物组合物优选为固体制剂、半固体制剂、液体制剂或气态制剂。A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a compound of any one of claims 1-11 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N- Oxides, isotopically-labeled compounds, metabolites or prodrugs, and a pharmaceutically acceptable carrier, the pharmaceutical composition is preferably a solid preparation, a semi-solid preparation, a liquid preparation or a gaseous preparation.
- 权利要求1-11中任一项的化合物或其药学上可接受的盐、酯、立体异构体、多晶型物、溶 剂合物、N-氧化物、同位素标记的化合物、代谢物或前药或者权利要求12的药物组合物在制备用作SOS1抑制剂的药物中的用途,优选地,所述药物用于预防或治疗癌症(例如胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤)、RAS病(例如1型神经纤维瘤病(NF1)、努南综合征(NS)、伴有多斑的努南综合征(NSML)、毛细血管畸形-动静脉畸形综合征(CM-AVM)、科斯特洛综合征(CS)、心-面-皮肤综合症(CFC)、莱格斯综合征和遗传性牙龈纤维瘤病)。The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or pro Use of the medicament or the pharmaceutical composition of claim 12 in the manufacture of a medicament for use as a SOS1 inhibitor, preferably for the prevention or treatment of cancer (eg pancreatic cancer, lung cancer, colorectal cancer, bile duct cancer, multiple Myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma tumor, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, kidney cancer and sarcoma), RAS diseases (e.g. neurofibromatosis type 1 (NF1), South syndrome (NS), Noonan syndrome with multiple spots (NSML), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Costello syndrome (CS), cardio-facial-cutaneous syndrome disease (CFC), Leggers syndrome and hereditary gingival fibromatosis).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180057482.2A CN116194446A (en) | 2020-08-06 | 2021-08-05 | SOS1 inhibitor, pharmaceutical composition containing same and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2020/107362 | 2020-08-06 | ||
CN2020107362 | 2020-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022028506A1 true WO2022028506A1 (en) | 2022-02-10 |
Family
ID=80120032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/110746 WO2022028506A1 (en) | 2020-08-06 | 2021-08-05 | Sos1 inhibitor, pharmaceutical composition containing same, and use therefor |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116194446A (en) |
TW (1) | TWI793704B (en) |
WO (1) | WO2022028506A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113912608A (en) * | 2020-07-10 | 2022-01-11 | 江苏恒瑞医药股份有限公司 | Pyrimidopyrimidinone derivatives, preparation method thereof and application thereof in medicines |
WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
WO2023008462A1 (en) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | Medicament for treatment and/or prevention of cancer |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006119504A2 (en) * | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
WO2008123963A1 (en) * | 2007-04-02 | 2008-10-16 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
CN101677569A (en) * | 2007-04-17 | 2010-03-24 | 雷诺维思公司 | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
CN110167928A (en) * | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | The quinazoline and derivative that Novel warp benzylamino as SOS1 inhibitor replaces |
CN111372932A (en) * | 2017-12-21 | 2020-07-03 | 勃林格殷格翰国际有限公司 | Novel benzylamino-substituted pyridopyrimidinones and derivatives as SOS1 inhibitors |
WO2020180770A1 (en) * | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
-
2021
- 2021-08-05 CN CN202180057482.2A patent/CN116194446A/en active Pending
- 2021-08-05 WO PCT/CN2021/110746 patent/WO2022028506A1/en active Application Filing
- 2021-08-05 TW TW110128940A patent/TWI793704B/en active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006119504A2 (en) * | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
WO2008123963A1 (en) * | 2007-04-02 | 2008-10-16 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
CN101677569A (en) * | 2007-04-17 | 2010-03-24 | 雷诺维思公司 | 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof |
CN110167928A (en) * | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | The quinazoline and derivative that Novel warp benzylamino as SOS1 inhibitor replaces |
CN111372932A (en) * | 2017-12-21 | 2020-07-03 | 勃林格殷格翰国际有限公司 | Novel benzylamino-substituted pyridopyrimidinones and derivatives as SOS1 inhibitors |
WO2020180770A1 (en) * | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
Non-Patent Citations (1)
Title |
---|
ROMAN C. HILLIG ET AL.: "Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction", PNAS, vol. 116, no. 7, 12 February 2019 (2019-02-12), XP055841142, ISSN: 0027-8424, DOI: 10.1073/pnas.1812963116 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113912608A (en) * | 2020-07-10 | 2022-01-11 | 江苏恒瑞医药股份有限公司 | Pyrimidopyrimidinone derivatives, preparation method thereof and application thereof in medicines |
WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
WO2023008462A1 (en) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | Medicament for treatment and/or prevention of cancer |
WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
Also Published As
Publication number | Publication date |
---|---|
TWI793704B (en) | 2023-02-21 |
TW202214629A (en) | 2022-04-16 |
CN116194446A (en) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107735399B (en) | Chiral diaryl macrocycles as modulators of protein kinases | |
JP2023126907A (en) | Rho-related protein kinase inhibitor, pharmaceutical composition containing the same, and method of preparation and use thereof | |
JP7039802B2 (en) | Pharmaceutical composition containing RHO-related protein kinase inhibitor, RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition. | |
WO2022028506A1 (en) | Sos1 inhibitor, pharmaceutical composition containing same, and use therefor | |
JP2020525525A (en) | RHO-related protein kinase inhibitor, pharmaceutical composition containing RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition | |
KR20210121168A (en) | Heterocyclic compound benzopyridone and its use | |
WO2018149284A1 (en) | Kinase inhibitor and preparation method therefor and use thereof | |
WO2019134539A1 (en) | Dihydropyrazolone and pyrimidine compound, preparation method and use therefor | |
WO2022121813A1 (en) | Sos1 inhibitor, pharmaceutical composition comprising same, and use thereof | |
TWI833819B (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
CN109071548A (en) | It can be used for treating the pyrroles's benzimidazole derivative or its analog of especially cancer | |
IL305046A (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
TW202214639A (en) | Pyridonelopyrimidine derivative, preparation method thereof, and medical use thereof | |
WO2021244659A1 (en) | Isotope-substituted spiro aromatic ring compound and application thereof | |
WO2022193871A1 (en) | Preparation and use of krasg12d mutant protein inhibitor | |
WO2018066718A1 (en) | Therapeutic compounds | |
TW202023550A (en) | Heteroaromatic compounds as vanin inhibitors | |
WO2021041976A1 (en) | Perk inhibiting indolinyl compounds | |
EP4382530A1 (en) | Shp2 inhibitor, pharmaceutical composition comprising same, and application thereof | |
WO2021041970A1 (en) | Perk inhibiting imidazolopyrazine compounds | |
WO2022237676A1 (en) | Preparation and application of shp2 phosphatase inhibitor | |
WO2022089389A1 (en) | Heterocyclic compound, preparation method therefor, pharmaceutical composition thereof and application thereof | |
CN112969694B (en) | Rho-associated protein kinase inhibitors, pharmaceutical compositions containing same and uses thereof | |
IL293107A (en) | Adenosine receptor antagonist compounds | |
CN111377873B (en) | Aminopyrimidine compounds, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21854598 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21854598 Country of ref document: EP Kind code of ref document: A1 |